<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="ba6ae57f-0729-4c8d-afc8-1e99a5a99871"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use VITRAKVI safely and effectively. See full prescribing information for VITRAKVI. <br/>
      <br/> VITRAKVI<sup>®</sup> (larotrectinib) capsules, for oral use <br/> VITRAKVI<sup>®</sup> (larotrectinib) oral solution <br/> Initial U.S. Approval: 2018</title>
   <effectiveTime value="20250430"/>
   <setId root="0c8ca614-58b2-4aa4-83d3-0387a8f782fd"/>
   <versionNumber value="11"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="005436809" root="1.3.6.1.4.1.519.1"/>
            <name>Bayer HealthCare Pharmaceuticals Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="226277259" root="1.3.6.1.4.1.519.1"/>
                        <name>Penn Pharmaceutical Services Ltd</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-393" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-390" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-391" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-392" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-393" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-390" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-391" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-392" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-393" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-390" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-391" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-392" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="788779192" root="1.3.6.1.4.1.519.1"/>
                        <name>W. R. Grace &amp; Co.-Conn.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-393" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-390" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-391" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-392" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="143696495" root="1.3.6.1.4.1.519.1"/>
                        <name>Sharp Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-390" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-391" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-390" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-391" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-392" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="539763727" root="1.3.6.1.4.1.519.1"/>
                        <name>Orion Corporation, Orion Pharma</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-393" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-390" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-391" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-392" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-393" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-393" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="493010524" root="1.3.6.1.4.1.519.1"/>
                        <name>NEXTPHARMA PLOERMEL</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-390" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-391" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="228216353" root="1.3.6.1.4.1.519.1"/>
                        <name>Wickham Micro Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-392" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="225081538" root="1.3.6.1.4.1.519.1"/>
                        <name>Butterworth Laboratories Ltd</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-392" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="331575303" root="1.3.6.1.4.1.519.1"/>
                        <name>Currenta GmbH &amp; Co. OHG</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-392" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="368380223" root="1.3.6.1.4.1.519.1"/>
                        <name>Orion Corporation, Orion Pharma</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-392" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-390" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-391" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-390" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-391" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="144616641" root="1.3.6.1.4.1.519.1"/>
                        <name>Avista Pharma Solutions, Inc. dba Cambrex</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-390" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50419-391" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2b5f258f-ff71-4b9d-ae7b-e9689f9f8ae5"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250430"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50419-390" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>VITRAKVI</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LAROTRECTINIB</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PF9462I9HX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LAROTRECTINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="PF9462I9HX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LAROTRECTINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50419-390-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190726"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210861" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190726"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>Opaque White</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">BAYER;25mg</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50419-391" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>VITRAKVI</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LAROTRECTINIB</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PF9462I9HX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LAROTRECTINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="PF9462I9HX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LAROTRECTINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50419-391-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190726"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210861" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190726"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>Opaque White</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">BAYER;100mg</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50419-392" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>VITRAKVI</name>
                        <formCode code="C42898" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION, CONCENTRATE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LAROTRECTINIB</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PF9462I9HX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LAROTRECTINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="PF9462I9HX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LAROTRECTINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="506T60A25R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="SE337SVY37" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1VPU26JZZ4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM SORBATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8W6Q67R6NX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ADRABETADEX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50419-392-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190726"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA211710" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190726"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE">
                              <originalText>Clear Yellow to Orange</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLFLAVOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C73365" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BERRY" xsi:type="CE">
                              <originalText>Citrus Berry</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38289" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OROPHARYNGEAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50419-393" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>VITRAKVI</name>
                        <formCode code="C42898" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION, CONCENTRATE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LAROTRECTINIB</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PF9462I9HX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LAROTRECTINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="PF9462I9HX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LAROTRECTINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1I96OHX6EK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL BETADEX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OJ245FE5EU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BENZOATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1Q73Q2JULR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CITRATE, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="96K6UQ3ZD4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCRALOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="50"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50419-393-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="2"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="50419-393-03" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20221206"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA211710" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20221206"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLFLAVOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C73417" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STRAWBERRY" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38289" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OROPHARYNGEAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="a0e739be-8133-45c1-b089-09959f8ff802"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="50%" align="left" valign="top"/>
                           <col width="50%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Indications and Usage (<linkHtml href="#S1">1</linkHtml>)</td>
                                 <td>4/2025</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#S2.1">2.1</linkHtml>)</td>
                                 <td>4/2025</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>)</td>
                                 <td>4/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="f76944d7-0b9a-4681-ac15-40c579bbf027"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="xmChange">have a neurotrophic receptor tyrosine kinase (<content styleCode="italics">NTRK</content>) gene fusion without a known acquired resistance mutation,</content>
                     </item>
                     <item>
                        <content styleCode="xmChange">are metastatic or where surgical resection is likely to result in severe morbidity, and </content>
                     </item>
                     <item>
                        <content styleCode="xmChange">have no satisfactory alternative treatments or that have progressed following treatment.</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="xmChange">Select patients for therapy based on an FDA-approved test <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>].</content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>have a neurotrophic receptor tyrosine kinase (<content styleCode="italics">NTRK</content>) gene fusion without a known acquired resistance mutation, </item>
                           <item>are metastatic or where surgical resection is likely to result in severe morbidity, and </item>
                           <item>have no satisfactory alternative treatments or that have progressed following treatment.</item>
                        </list>
                        <paragraph>Select patients for therapy based on an FDA-approved test. (<linkHtml href="#S1">1</linkHtml>, <linkHtml href="#S2.1">2.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="08fdb6a4-044c-4099-90ee-ef57c0cc07be"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Select patients for treatment with VITRAKVI based on the presence of a <content styleCode="italics">NTRK</content> gene fusion (<linkHtml href="#S2.1">2.1</linkHtml>, <linkHtml href="#S14">14</linkHtml>).</item>
                           <item>Recommended Dosage in Adult and Pediatric Patients with Body Surface Area of 1 Meter-Squared or greater: 100 mg orally twice daily (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>Recommended Dosage in Pediatric Patients with Body Surface Area of Less Than 1 Meter-Squared: 100 mg/m<sup>2</sup> orally twice daily (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="9f031a0a-d996-48db-a399-6e51d976a7dc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	 Patient Selection</title>
                     <text>
                        <paragraph>Select patients for treatment with VITRAKVI based on the presence of a <content styleCode="italics">NTRK</content> gene fusion in tumor specimens <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In patients with secretory breast cancer, mammary analogue secretory cancer (MASC), congenital mesoblastic nephroma (CMN), or infantile fibrosarcoma, consider treatment without confirmation of <content styleCode="italics">NTRK</content> rearrangements in tumor specimens.</content>
                        </paragraph>
                        <paragraph>Information on FDA-approved tests is available at http://www.fda.gov/companiondiagnostics. </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="65445be4-d31f-4078-ac8c-5b93d1e1242c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	 Recommended Dosage</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="8b709258-05d0-46a1-8f6f-aabe2da978c9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Recommended Dosage in Adult and Pediatric Patients with Body Surface Area of 1 Meter-Squared or greater </paragraph>
                              <paragraph>The recommended dosage of VITRAKVI is 100 mg orally twice daily, with or without food, until disease progression or until unacceptable toxicity.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="92f4336f-1ab1-4592-84f2-7269b168364d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Recommended Dosage in Pediatric Patients with Body Surface Area Less Than 1 Meter-Squared</paragraph>
                              <paragraph>The recommended dosage of VITRAKVI is 100 mg/m<sup>2</sup> orally twice daily, with or without food, until disease progression or until unacceptable toxicity.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="57d863c5-e939-4368-aaa8-ddeafc51045c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 	Dosage Modifications for Adverse Reactions</title>
                     <text>
                        <paragraph>For Grade 2 and higher liver function test abnormalities, refer to Section 2.4, Table 2, Dosage Modifications for Hepatotoxicity. </paragraph>
                        <paragraph>For all other Grade 3 or 4 adverse reactions:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Withhold VITRAKVI until adverse reaction resolves or improves to baseline or Grade 1. Resume at the next dosage modification if resolution occurs within 4 weeks.</item>
                           <item>Permanently discontinue VITRAKVI if an adverse reaction does not resolve within 4 weeks.</item>
                        </list>
                        <paragraph>The recommended dosage reductions for VITRAKVI for adverse reactions are provided in Table 1.</paragraph>
                        <table width="80%">
                           <caption>Table 1 	Recommended Dosage Reductions for VITRAKVI for Adverse Reactions</caption>
                           <col width="34%" align="left" valign="top"/>
                           <col width="33%" align="center" valign="middle"/>
                           <col width="33%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="botrule">
                                 <th styleCode="Lrule Rrule" valign="bottom">Dosage Reduction</th>
                                 <th styleCode="Rrule">Adult and Pediatric Patients with Body Surface Area of 1 m<sup>2</sup> or Greater</th>
                                 <th styleCode="Rrule">Pediatric Patients with Body Surface Area Less Than 1 m<sup>2</sup>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule bold">First </td>
                                 <td styleCode="Rrule">75 mg orally twice daily</td>
                                 <td styleCode="Rrule">75 mg/m<sup>2</sup> orally twice daily</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule bold">Second </td>
                                 <td styleCode="Rrule">50 mg orally twice daily</td>
                                 <td styleCode="Rrule">50 mg/m<sup>2</sup> orally twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule bold">Third </td>
                                 <td styleCode="Rrule">100 mg orally once daily</td>
                                 <td styleCode="Rrule">25 mg/m<sup>2</sup> orally twice daily<footnote ID="t1a">Pediatric patients on 25 mg/m<sup>2</sup> orally twice daily should remain on this dosage even if body surface area becomes greater than 1 m<sup>2</sup> during the treatment. Maximum dose should be 25 mg/m<sup>2</sup> orally twice daily at the third dosage modification.</footnote>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Permanently discontinue VITRAKVI in patients who are unable to tolerate VITRAKVI after three dose modifications.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="05502661-5a8e-4828-9ba5-8cabd1872190"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	 Dosage Modifications for Hepatotoxicity</title>
                     <text>
                        <paragraph>The recommended dosage modifications for VITRAKVI liver function test abnormalities are provided in Table 2.</paragraph>
                        <paragraph>For CTCAE Grade 2 ALT and/or AST elevation, monitor liver function frequently as clinically indicated, to establish whether a dose interruption or reduction is required <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>. </paragraph>
                        <table width="80%">
                           <caption>Table 2	 Recommended Dosage Modifications for VITRAKVI for Hepatotoxicity</caption>
                           <col width="30%" align="left" valign="middle"/>
                           <col width="70%" align="left" valign="middle"/>
                           <thead>
                              <tr styleCode="botrule">
                                 <th styleCode="Lrule Rrule">Severity<footnote ID="t2a">Grading defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03</footnote>
                                 </th>
                                 <th styleCode="Rrule" align="center">Dosage Modification</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="2">ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule bold">AST or ALT ≥ 5 × ULN  with bilirubin ≤ 2 × ULN <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Withhold VITRAKVI until recovery to ≤ Grade 1 or return to baseline. </item>
                                       <item>Resume VITRAKVI at the next lower dose level. </item>
                                       <item>Permanently discontinue if a Grade 4 AST and/or ALT elevation occurs after resuming VITRAKVI.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule bold">AST or ALT &gt; 3 × ULN with total bilirubin &gt; 2 × ULN in the absence of alternative causes</td>
                                 <td styleCode="Rrule">
                                    <list listType="unordered" styleCode="disc">
                                       <item>Permanently discontinue VITRAKVI.</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="e584909a-362b-4dde-856c-083403e8b56d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5	 Dosage Modifications for Coadministration with Strong CYP3A4 Inhibitors </title>
                     <text>
                        <paragraph>Avoid coadministration of strong CYP3A4 inhibitors with VITRAKVI. If coadministration of a strong CYP3A4 inhibitor cannot be avoided, reduce the VITRAKVI dose by 50%. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, resume the VITRAKVI dose that was used prior to initiating the CYP3A4 inhibitor <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="88cb6421-d52e-4a39-965d-537c436a0256"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 	Dosage Modifications for Coadministration with Strong or Moderate CYP3A4 Inducers </title>
                     <text>
                        <paragraph>Avoid coadministration of strong CYP3A4 inducers with VITRAKVI. If coadministration of a strong CYP3A4 inducer cannot be avoided, double the VITRAKVI dose. Additionally, for coadministration with a moderate CYP3A4 inducer, double the VITRAKVI dose. After the inducer has been discontinued for 3 to 5 elimination half-lives, resume the VITRAKVI dose that was used prior to initiating the CYP3A4 inducer <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.7">
                     <id root="4782c0b1-4600-4ad7-978e-a91e5f89d611"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7	 Dosage Modifications for Patients with Hepatic Impairment</title>
                     <text>
                        <paragraph>Reduce the starting dose of VITRAKVI by 50% in patients with moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.8">
                     <id root="adf6a048-dc14-4f5f-9f3c-0619cbfc402d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.8 	Administration</title>
                     <text>
                        <paragraph>VITRAKVI capsule or oral solution may be used interchangeably.</paragraph>
                        <paragraph>Do not make up a missed dose within 6 hours of the next scheduled dose.</paragraph>
                        <paragraph>If vomiting occurs after taking a dose of VITRAKVI, take the next dose at the scheduled time.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="dbf644bc-7284-4afc-afea-d5274a7c48d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Capsules</paragraph>
                              <paragraph>Swallow capsules whole with water. Do not chew or crush the capsules.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="00473a60-150d-422e-bb94-c652e742ba17"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Oral Solution packaged in one bottle containing 100 mL </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Store the glass bottle of VITRAKVI oral solution in the refrigerator. Discard any unused VITRAKVI oral solution remaining after 90 days of first opening the bottle.</item>
                                 <item>Prior to preparing an oral dose for administration, refer to the Instructions for Use.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="623fe977-5df2-4354-aa29-4bcdb5a23e7a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Oral Solution packaged in two bottles each containing 50 mL </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Store the glass bottles of VITRAKVI oral solution in the refrigerator. Discard any unused VITRAKVI oral solution remaining after 31 days of first opening the bottle.</item>
                                 <item>Prior to preparing an oral dose for administration, refer to the Instructions for Use.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="3abaf4b0-98e2-41ae-80d2-45c3096adf69"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Capsules: 25 mg, 100 mg (<linkHtml href="#S3">3</linkHtml>)</item>
                           <item>Oral Solution: 20 mg/mL (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="40ae2d58-0653-4eab-8941-1473409b632f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph styleCode="underline">Capsules</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>25 mg: white opaque hard gelatin capsule, size 2, with blue printing of "BAYER" cross and "25 mg" on body of capsules. 25 mg larotrectinib is equivalent to 30.7 mg larotrectinib sulfate.</item>
                           <item>100 mg: white opaque hard gelatin capsule, size 0, with blue printing of "BAYER" cross and "100 mg" on body of capsule. 100 mg larotrectinib is equivalent to 123 mg larotrectinib sulfate.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="edb66578-0b8e-43ce-85eb-d3e2fd61c3a0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph styleCode="underline">Oral Solution packaged in one bottle containing 100 mL</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>20 mg/mL: clear yellow to orange solution. 20 mg/mL larotrectinib is equivalent to 24.6 mg/mL larotrectinib sulfate. </item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="a8d7b90b-ae2e-4d66-b283-17ab35495716"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph styleCode="underline">Oral Solution packaged in two bottles each containing 50 mL </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>20 mg/mL: colorless to yellow or orange or red or brownish solution. 20 mg/mL larotrectinib is equivalent to 24.6 mg/mL larotrectinib sulfate. </item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="79e486bf-35df-4375-8fca-8a715569c150"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="12f89a0a-a733-42d0-aaf3-f28e5a515f6e"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Central Nervous System (CNS) Effects: Advise patients and caretakers of the risk of CNS adverse reactions including dizziness, cognitive impairment, mood disorders, and sleep disturbances. Advise patients not to drive or operate hazardous machinery if experiencing neurotoxicity. Withhold and modify dosage, or permanently discontinue VITRAKVI based on severity. (<linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>Skeletal Fractures: Promptly evaluate patients with signs or symptoms of fractures. (<linkHtml href="#S5.2">5.2</linkHtml>) </item>
                           <item>Hepatotoxicity: Obtain liver function tests (ALT, AST, ALP and bilirubin) before initiation of VITRAKVI and every 2 weeks during the first 2 months of treatment, then monthly thereafter or as clinically indicated. Temporarily withhold, reduce dose, or permanently discontinue VITRAKVI based on severity. (<linkHtml href="#S2.4">2.4</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>Embryo-Fetal Toxicity: Can cause fetal harm. Advise females with reproductive potential of potential risk to the fetus and to use effective contraception. (<linkHtml href="#S5.4">5.4</linkHtml>, <linkHtml href="#S8.3">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="5d3293fa-ed53-4a06-9809-d8191bc02549"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	 Central Nervous System Effects  </title>
                     <text>
                        <paragraph>Central nervous system (CNS) adverse reactions occurred in patients receiving VITRAKVI, including dizziness, cognitive impairment, mood disorders, and sleep disturbances.</paragraph>
                        <paragraph>In patients who received VITRAKVI (n=444), all grades CNS effects including cognitive impairment, mood disorders, dizziness and sleep disorders were observed in 40.3% with Grades 3-4 in 3.8% of patients. </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Cognitive impairment occurred in 11% of patients. The median time to onset of cognitive impairment was 6 months (range: 2 days to 56 months). Cognitive impairment occurring in ≥ 1% of patients included memory impairment (4.1%), disturbance in attention (3.6%), confusional state (2.3%), cognitive disorder (1.6%), delirium (1.4%), and hallucination (1.1%). Grade 3 cognitive adverse reactions occurred in 1.8% of patients and Grade 4 cognitive adverse reactions in 0.2% of patients. Among the 49 patients with cognitive impairment, 6% required a dose modification, and 18% required dose interruption.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Mood disorders occurred in 14% of patients. The median time to onset of mood disorders was 3.3 months (range: 1 day to 65 months). Mood disorders occurring in ≥ 1% of patients included anxiety (5%), agitation (3.2%), depression (3.2%), irritability (2.3%), and restlessness (1.1%). Grade 3 mood disorders occurred in 0.9% of patients. Among the 63 patients who experienced mood disorders, no patient required a dose modification, and 1.6% required dose interruption.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Dizziness occurred in 22% of patients, and Grade 3 dizziness occurred in 0.9% of patients. Among the 96 patients who experienced dizziness, 6% of patients required a dose modification, and 5% required dose interruption.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Sleep disturbances occurred in 12% of patients. Sleep disturbances included insomnia (9%), somnolence (3.4%), and sleep disorder (0.5%). Grade 3 sleep disturbances occurred in 0.2% of patients. Among the 54 patients who experienced sleep disturbances, no patient required a dose modification, and 3.7% required dose interruption.</content>
                        </paragraph>
                        <paragraph>Advise patients and caretakers of these risks with VITRAKVI. Advise patients not to drive or operate hazardous machinery if they are experiencing neurologic adverse reactions. Withhold or permanently discontinue VITRAKVI based on the severity. If withheld, modify the VITRAKVI dosage when resumed <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="d4f27a82-4fdf-4416-90c4-74d790d9e84a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	 Skeletal Fractures</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Skeletal fractures can occur in patients taking VITRAKVI. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Among 444 patients who received VITRAKVI across clinical trials, fractures occurred in 7% of patients; 6% of 290 adult patients and 10% of 154 pediatric patients. Median time to first fracture was 13 months (range 27 days to 73 months) in patients followed per fracture. The most common fractures were of the rib (1.4%), fibula, foot, or wrist (0.7% each). Most fractures were associated with minimal or moderate trauma. Some fractures were associated with radiologic abnormalities suggestive of local tumor involvement. VITRAKVI treatment was interrupted due to fracture in 1.4% patients. </content>
                        </paragraph>
                        <paragraph>Promptly evaluate patients with signs or symptoms of potential fracture (e.g., pain, changes in mobility, deformity). There are no data on the effects of VITRAKVI on healing of known fractures or risk of future fractures.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="c71fe1a9-a66f-451d-a692-a5adb40ffdf3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	 Hepatotoxicity</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Hepatotoxicity including drug-induced liver injury (DILI) has occurred in patients taking VITRAKVI. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In patients who received VITRAKVI (n=444), increased AST of any grade occurred in 62% of patients and increased ALT of any grade occurred in 61%. Grade 3-4 increased AST or ALT occurred in 7% and 8% of patients, respectively <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. The median time to onset of increased AST was 1.9 months (range: 4 days to 3.8 years). The median time to onset of increased ALT was 1.9 months (range: 1 day to 4.9 years). Increased AST and ALT leading to dose modifications occurred in 1.6% and 3.2% of patients, respectively. Increased AST or ALT led to permanent discontinuation in 4 (0.9%) patients.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">There have been reports from clinical studies and postmarketing cases of Grade ≥ 2 increases in ALT and/or AST with increases in bilirubin ≥ 2 × ULN.</content>
                        </paragraph>
                        <paragraph>Obtain liver function tests (ALT, AST, ALP and bilirubin) before initiation of VITRAKVI and monitor every 2 weeks during the first 2 months of treatment, then monthly thereafter, or more frequently following the occurrence of Grade 2 or greater AST or ALT elevation. Temporarily withhold, reduce the dose, or permanently discontinue VITRAKVI based on severity <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="7519b0b8-47db-4a6e-b323-f247032ac31c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on literature reports in human subjects with congenital mutations leading to changes in TRK signaling, findings from animal studies, and its mechanism of action, VITRAKVI can cause fetal harm when administered to a pregnant woman. Larotrectinib resulted in malformations in rats and rabbits at maternal exposures that were approximately 11- and 0.7-times, respectively, those observed at the clinical dose of 100 mg twice daily. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment and for 1 week after the last dose of VITRAKVI <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="617a1eab-01cc-4534-8903-899018deda20"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Central Nervous System Effects <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Skeletal Fractures <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common (≥ 20%) adverse reactions, including laboratory abnormalities, with VITRAKVI were increased AST, increased ALT, anemia, hypoalbuminemia, musculoskeletal pain, increased alkaline phosphatase, leukopenia, lymphopenia, neutropenia, hypocalcemia, fatigue, vomiting, cough, constipation, pyrexia, diarrhea, nausea, abdominal pain, dizziness, and rash (<linkHtml href="#S6">6</linkHtml>).</paragraph>
                        <br/>
                        <paragraph styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch<content styleCode="bold italics">.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="46bd0be8-89bc-4415-932c-cecf9c675a48"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>Unless noted, data in WARNINGS AND PRECAUTIONS and below reflects exposure to VITRAKVI in 444 patients, including 62% patients exposed for greater than 6 months, 44% patients exposed for greater than 1 year, and 30% patients exposed for greater than 2 years. VITRAKVI was studied in one adult dose-finding trial [LOXO-TRK-14001 (n = 75)], one pediatric dose-finding trial [SCOUT (n = 154)], and one single arm trial [NAVIGATE (n = 215)]. All patients had an unresectable or metastatic solid tumor and no satisfactory alternative treatment options or disease progression following treatment.</paragraph>
                        <paragraph>Across these 444 patients, the median age was 44 years (range: 18 days to 90 years); 35% were younger than 18 years; 53% were female; 59% were White, 24% were Asian and, 4% were Black; and 7% were Hispanic/Latino. Most adults (91%) received VITRAKVI 100 mg orally twice daily and 91% of pediatrics (&lt; 18 years) received VITRAKVI 100 mg/m<sup>2</sup> twice daily up to a maximum dose of 100 mg twice daily. The dose ranged from 50 mg daily to 200 mg twice daily in adults and 9.6 mg/m<sup>2</sup> twice daily to 120 mg/m<sup>2</sup> twice daily in pediatrics <content styleCode="italics">[see <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
                        <paragraph>The most common serious adverse reactions (≥ 2%) were pneumonia, pyrexia, and dyspnea. Grade 3 or 4 adverse reactions occurred in 60% of patients; adverse reactions leading to dose interruption or modification occurred in 45% and 11% of patients, respectively, and 12% permanently discontinued VITRAKVI for adverse reactions. </paragraph>
                        <paragraph>The most common adverse reactions (1% each) that resulted in permanent discontinuation of VITRAKVI were increased ALT and increased AST. </paragraph>
                        <paragraph>The most common adverse reactions (≥ 3%) resulting in dose interruption were increased ALT (6%), increased AST (5%), neutrophil count decreased (4.7%), pyrexia (4.3%), and vomiting (3.2%). Most (64%) adverse reactions leading to dose interruption occurred during the first three months of exposure.</paragraph>
                        <paragraph>The most common adverse reactions (≥ 20%), including laboratory abnormalities, in order of decreasing frequency were increased AST, increased ALT, anemia, hypoalbuminemia, musculoskeletal pain, increased alkaline phosphatase, leukopenia, lymphopenia, neutropenia, hypocalcemia, fatigue, vomiting, cough, constipation, pyrexia, diarrhea, nausea, abdominal pain, dizziness, and rash. </paragraph>
                        <paragraph>Adverse reactions of VITRAKVI occurring in ≥ 10% of patients and laboratory abnormalities worsening from baseline in ≥ 20% of patients are summarized in Table 3 and Table 4, respectively. </paragraph>
                        <table width="80%">
                           <caption>Table 3 	Adverse Reactions Occurring in ≥ 10% of Patients Treated with VITRAKVI</caption>
                           <col width="34%" align="left" valign="middle"/>
                           <col width="33%" align="center" valign="middle"/>
                           <col width="33%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="botrule">
                                 <th styleCode="Lrule Rrule" rowspan="2">Adverse Reaction<footnote>The adverse reaction identifies a composite term:</footnote>
                                 </th>
                                 <th styleCode="Rrule" colspan="2">VITRAKVI <br/> N = 444</th>
                              </tr>
                              <tr>
                                 <th styleCode="Rrule" align="center">All Grades<footnote>National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 4.03.</footnote>
                                    <br/> (%)</th>
                                 <th styleCode="Rrule" align="center">Grade 3-4<footnote>Grade 4 adverse reaction: 1 of cognitive impairment, 1 of pyrexia. </footnote>
                                    <br/> (%)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Musculoskeletal and Connective Tissue </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Musculoskeletal Pain<footnote>Includes: arthralgia, back pain, bone pain, flank pain, groin pain, growing pains, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, musculoskeletal stiffness, myalgia, neck pain, non-cardiac chest pain, pain in extremity, pain in jaw, and tendon pain</footnote>
                                 </td>
                                 <td styleCode="Rrule">41</td>
                                 <td styleCode="Rrule">3.6</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">General</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Fatigue<footnote>Includes: fatigue, asthenia</footnote>
                                 </td>
                                 <td styleCode="Rrule">31</td>
                                 <td styleCode="Rrule">2.5</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Pyrexia</td>
                                 <td styleCode="Rrule">26</td>
                                 <td styleCode="Rrule">2.3</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Edema<footnote>Includes: face edema, generalized edema, lip edema, localized edema, edema, edema genital, edema peripheral, periorbital edema, and swelling</footnote>
                                 </td>
                                 <td styleCode="Rrule">17</td>
                                 <td styleCode="Rrule">0.7</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Respiratory, Thoracic and Mediastinal </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Cough<footnote>Includes: cough, productive cough, and upper-airway cough syndrome</footnote>
                                 </td>
                                 <td styleCode="Rrule">29</td>
                                 <td styleCode="Rrule">0.5</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Dyspnea<footnote>Includes: dyspnea, and dyspnea exertional</footnote>
                                 </td>
                                 <td styleCode="Rrule">17</td>
                                 <td styleCode="Rrule">2.7</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Nasal congestion</td>
                                 <td styleCode="Rrule">10</td>
                                 <td styleCode="Rrule">0</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Nervous System </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Dizziness<footnote>Includes: dizziness, dizziness postural, and vertigo</footnote>
                                 </td>
                                 <td styleCode="Rrule">22</td>
                                 <td styleCode="Rrule">0.9</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Headache</td>
                                 <td styleCode="Rrule">17</td>
                                 <td styleCode="Rrule">0.9</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Cognitive Impairment<footnote>Includes: amnesia, aphasia, cognitive disorder, confusional state, delirium, disturbance in attention, hallucination, hallucination visual, memory impairment, mental impairment, mental status changes</footnote>
                                 </td>
                                 <td styleCode="Rrule">11</td>
                                 <td styleCode="Rrule">2</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Gastrointestinal </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Vomiting</td>
                                 <td styleCode="Rrule">30</td>
                                 <td styleCode="Rrule">1.1</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Constipation</td>
                                 <td styleCode="Rrule">27</td>
                                 <td styleCode="Rrule">0.5</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Diarrhea</td>
                                 <td styleCode="Rrule">26</td>
                                 <td styleCode="Rrule">2.9</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Nausea</td>
                                 <td styleCode="Rrule">25</td>
                                 <td styleCode="Rrule">0.5</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Abdominal pain<footnote>Includes: abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, epigastric discomfort, and gastrointestinal pain</footnote>
                                 </td>
                                 <td styleCode="Rrule">24</td>
                                 <td styleCode="Rrule">1.4</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Skin and Subcutaneous Tissue Disorders</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Rash<footnote>Includes: dermatitis, dermatitis acneiform, dermatitis bullous, dermatitis exfoliative generalized, eczema, eczema asteatotic, palmar-plantar erythrodysaesthesia syndrome, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, and rash pustular</footnote>
                                 </td>
                                 <td styleCode="Rrule">21</td>
                                 <td styleCode="Rrule">0.2</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Psychiatric</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Mood disorders<footnote>Includes: agitation, anxiety, depression, depressed mood, euphoric mood, fear, feeling jittery, irritability, panic attack, psychomotor hyperactivity, restlessness</footnote>
                                 </td>
                                 <td styleCode="Rrule">14</td>
                                 <td styleCode="Rrule">0.9</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Sleep Disturbance<footnote>Includes: insomnia, sleep disorder, somnolence</footnote>
                                 </td>
                                 <td styleCode="Rrule">12</td>
                                 <td styleCode="Rrule">0.2</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Investigations</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Increased weight</td>
                                 <td styleCode="Rrule">17</td>
                                 <td styleCode="Rrule">4.1</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Metabolism and Nutrition </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Decreased appetite</td>
                                 <td styleCode="Rrule">14</td>
                                 <td styleCode="Rrule">1.1</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Infections and Infestations                                                                                                                                            </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Upper respiratory tract infection</td>
                                 <td styleCode="Rrule">18</td>
                                 <td styleCode="Rrule">0.7</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Urinary tract infection<footnote>Includes: cystitis, cystitis escherichia, escherichia urinary tract infection, kidney infection, pyelonephritis, pyelonephritis acute, pyelonephritis chronic, and urinary tract infection</footnote>
                                 </td>
                                 <td styleCode="Rrule">14</td>
                                 <td styleCode="Rrule">1.8</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Nasopharyngitis</td>
                                 <td styleCode="Rrule">11</td>
                                 <td styleCode="Rrule">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Clinically relevant adverse reactions occurring in ≤ 10% of patients include fractures (7%). </paragraph>
                        <table width="80%">
                           <caption>Table 4	Laboratory Abnormalities Occurring in ≥ 20% Patients Treated with VITRAKVI</caption>
                           <col width="34%" align="left" valign="middle"/>
                           <col width="33%" align="center" valign="middle"/>
                           <col width="33%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="botrule">
                                 <th styleCode="Lrule Rrule" rowspan="2">Laboratory Abnormality</th>
                                 <th styleCode="Rrule" colspan="2" align="center">VITRAKVI<footnote>Based on NCI CTCAE v4.03</footnote>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule" align="center" valign="top">All Grades (%)<footnote ID="t42">Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available which ranged from 416 to 442 patients.</footnote>
                                 </th>
                                 <th styleCode="Rrule" valign="top">Grade 3-4 <br/> (%)<footnoteRef IDREF="t42"/>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Chemistry</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Increased AST</td>
                                 <td styleCode="Rrule">62</td>
                                 <td styleCode="Rrule">7</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Increased ALT</td>
                                 <td styleCode="Rrule">61</td>
                                 <td styleCode="Rrule">8</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Hypoalbuminemia</td>
                                 <td styleCode="Rrule">44</td>
                                 <td styleCode="Rrule">2.7</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Increased alkaline phosphatase</td>
                                 <td styleCode="Rrule">40</td>
                                 <td styleCode="Rrule">3</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Hypocalcemia</td>
                                 <td styleCode="Rrule">32</td>
                                 <td styleCode="Rrule">3.1</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Hematology</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Anemia</td>
                                 <td styleCode="Rrule">45</td>
                                 <td styleCode="Rrule">8</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Leukopenia</td>
                                 <td styleCode="Rrule">37</td>
                                 <td styleCode="Rrule">3.8</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Lymphopenia</td>
                                 <td styleCode="Rrule">35</td>
                                 <td styleCode="Rrule">11</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">   Neutropenia</td>
                                 <td styleCode="Rrule">34</td>
                                 <td styleCode="Rrule">11</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="3ff1bc52-35b4-4fa5-820e-cbb1427719de"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Strong CYP3A4 Inhibitors: Avoid coadministration of strong CYP3A4 inhibitors with VITRAKVI. If coadministration cannot be avoided, reduce the VITRAKVI dose. (<linkHtml href="#S2.5">2.5</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Moderate CYP3A4 Inhibitors: Monitor for adverse reactions more frequently in patients coadministered a moderate CYP3A4 inhibitor with VITRAKVI and reduce the VITRAKVI dosage based on severity of adverse reactions. (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Strong CYP3A4 Inducers: Avoid coadministration of strong CYP3A4 inducers with VITRAKVI. If coadministration cannot be avoided, increase the VITRAKVI dose. (<linkHtml href="#S2.6">2.6</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Moderate CYP3A4 Inducers: Increase the VITRAKVI dose. (<linkHtml href="#S2.6">2.6</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Sensitive CYP3A4 Substrates: Avoid coadministration of sensitive CYP3A4 substrates with VITRAKVI. (<linkHtml href="#S7.2">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="a9ecd3ee-d261-47ef-85ea-960952525143"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	 Effects of Other Drugs on VITRAKVI</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="1a630717-5ef4-4c7f-9ae4-c143bb6352b5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Strong and Moderate CYP3A4 Inhibitors</paragraph>
                              <paragraph>Coadministration of VITRAKVI with a strong or moderate CYP3A4 inhibitor may increase larotrectinib plasma concentrations, which may result in a higher incidence of adverse reactions <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content> Avoid coadministration of VITRAKVI with strong CYP3A4 inhibitors, including grapefruit or grapefruit juice. If coadministration of strong CYP3A4 inhibitors cannot be avoided, modify VITRAKVI dose as recommended <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>]</content>. In patients coadministered a moderate CYP3A4 inhibitor with VITRAKVI, monitor for adverse reactions more frequently and reduce the VITRAKVI dosage based on the severity of emergent adverse reactions <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>. </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ee65a17a-c0e2-457d-b4a5-419ac7ba93df"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Strong and Moderate CYP3A4 Inducers</paragraph>
                              <paragraph>Coadministration of VITRAKVI with a strong or moderate CYP3A4 inducer may decrease larotrectinib plasma concentrations, which may decrease the efficacy of VITRAKVI <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content> Avoid coadministration of VITRAKVI with strong CYP3A4 inducers, including St. John's wort. If coadministration of strong CYP3A4 inducers cannot be avoided, modify VITRAKVI dose as recommended. For coadministration with moderate CYP3A4 inducers, modify VITRAKVI dose as recommended <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="6b4de14e-528b-4298-bd00-0401629d5dab"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 	Effects of VITRAKVI on Other Drugs</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="7d868f25-3d84-4cbc-b780-dcfa09ba2e74"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Sensitive CYP3A4 Substrates</paragraph>
                              <paragraph>Coadministration of VITRAKVI with sensitive CYP3A4 substrates may increase their plasma concentrations, which may increase the incidence or severity of adverse reactions <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Avoid coadministration of VITRAKVI with sensitive CYP3A4 substrates. If coadministration of these sensitive CYP3A4 substrates cannot be avoided, monitor patients for increased adverse reactions of these drugs.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="872860cd-57ed-430b-9796-cdd32ac7feed"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Lactation: Advise not to breastfeed. (<linkHtml href="#S8.2">8.2</linkHtml>)</item>
                           <item>Hepatic Impairment: Reduce the starting dose of VITRAKVI in patients with moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment. (<linkHtml href="#S2.7">2.7</linkHtml>, <linkHtml href="#S8.7">8.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="126af7f9-1d18-4845-a4f2-4a66959d1685"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="0388cbcb-2e32-407c-a9a4-a2ad964dcfa8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Risk Summary</paragraph>
                              <paragraph>Based on literature reports in human subjects with congenital mutations leading to changes in TRK signaling, findings from animal studies, and its mechanism of action <content styleCode="italics">[see <linkHtml href="#S12.1">Clinical Pharmacology (12.1)</linkHtml>]</content>, VITRAKVI can cause embryo-fetal harm when administered to a pregnant woman. There are no available data on VITRAKVI use in pregnant women. Administration of larotrectinib to pregnant rats and rabbits during the period of organogenesis resulted in malformations at maternal exposures that were approximately 11- and 0.7-times, respectively, those observed at the clinical dose of 100 mg twice daily <content styleCode="italics">(see <linkHtml href="#data1">Data</linkHtml>)</content>. Advise pregnant women of the potential risk to a fetus. </paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data1">
                           <id root="1891ee2b-8219-491a-b693-18ba6b370167"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Data</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="6de431eb-7c1d-48f3-a15f-1d3e5d66382a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph styleCode="italics">Human Data</paragraph>
                                    <paragraph>Published reports of individuals with congenital mutations in TRK pathway proteins suggest that decreases in TRK-mediated signaling are correlated with obesity, developmental delays, cognitive impairment, insensitivity to pain, and anhidrosis.</paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="70754b9b-04a8-4b89-b4d4-9855774b9a8f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph styleCode="italics">Animal Data</paragraph>
                                    <paragraph>Larotrectinib crosses the placenta in animals. Larotrectinib did not result in embryolethality at maternally toxic doses [up to 40 times the human exposure based on area under the curve (AUC) at the clinical dose of 100 mg twice daily] in embryo-fetal development studies in pregnant rats dosed during the period of organogenesis; however, larotrectinib was associated with fetal anasarca in rats from dams treated at twice-daily doses of 40 mg/kg [11 times the human exposure (AUC) at the clinical dose of 100 mg twice daily]. In pregnant rabbits, larotrectinib administration was associated with omphalocele at twice-daily doses of 15 mg/kg (0.7 times the human exposure at the clinical dose of 100 mg twice daily). </paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="7746f0db-a959-4bd9-b9d4-382d44c405b4"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="448008e6-82e0-4e9a-8dc4-70e377711dfd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Risk Summary</paragraph>
                              <paragraph>There are no data on the presence of larotrectinib or its metabolites in human milk and no data on its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with larotrectinib and for 1 week after the last dose. </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="471f3a6f-f40f-4d02-b901-3897f2dd128f"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="21390576-aeee-4233-9f4c-dce3b733cd04"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Pregnancy Testing</paragraph>
                              <paragraph>Verify pregnancy status in females of reproductive potential prior to initiating VITRAKVI <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="25133db5-2917-4591-aadd-32993fd5c484"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Contraception</paragraph>
                              <paragraph>VITRAKVI can cause embryo-fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="d54e5904-9cab-4fd8-8c0e-712901410f94"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph styleCode="italics">Females</paragraph>
                                    <paragraph>Advise female patients of reproductive potential to use effective contraception during treatment with VITRAKVI and for 1 week after the last dose. </paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="582780a7-16c9-409f-a00b-e883450fe1e6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph styleCode="italics">Males</paragraph>
                                    <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment with VITRAKVI and for 1 week after the last dose. </paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="aa661152-1871-4131-a1e2-6a2ba66b1f1e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Infertility</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="6b87ed16-bb5e-4494-a2e7-eb3a9632ee12"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph styleCode="italics">Females</paragraph>
                                    <paragraph>Based on histopathological findings in the reproductive tracts of female rats in a 1-month repeated-dose study, VITRAKVI may reduce fertility <content styleCode="italics">[See <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="be08131e-fd90-4706-8ca4-e8068329d6c5"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of VITRAKVI in pediatric patients was established based upon data from three multicenter, open-label, single-arm clinical trials in adult or pediatric patients. <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>, <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]. </content>
                        </paragraph>
                        <paragraph>The efficacy of VITRAKVI was evaluated in 131 pediatric patients and is described in the Clinical Studies section <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. The safety of VITRAKVI was evaluated in 154 pediatric patients who received VITRAKVI. Of these 154 patients, 31% were &lt;1 month to &lt; 2 years (n = 47), 49% were 2 years to &lt; 12 years (n = 75), and 21% were 12 years to &lt; 18 years (n = 32); 25% had metastatic disease, 44% had locally advanced disease, and 31% had primary CNS; and 82% had received prior treatment for their cancer, including surgery, radiotherapy, or systemic therapy, including radioactive iodine therapy (RAI). The most common cancers were infantile fibrosarcoma (32%), primary CNS tumors (31%), soft tissue sarcoma (27%), and thyroid cancer (4%). The median duration of exposure was 14.8 months (range: 0.4 months to 87.4 months). </paragraph>
                        <paragraph>Due to the small number of pediatric and adult patients, the single arm design of clinical studies of VITRAKVI, and confounding factors such as differences in susceptibility to infections between pediatric and adult patients, it is not possible to determine whether differences in the incidence of adverse reactions to VITRAKVI are related to patient age or other factors. Adverse reactions occurring more frequently (at least a 10% increase in per-patient incidence) in pediatric patients compared to adult patients were vomiting (51% versus 18%), pyrexia (47% versus 15%), cough (36% versus 23%), diarrhea (34% versus 21%), upper respiratory tract infection (33% versus 10%), headache (25% versus 13%), nasopharyngitis (20% versus 7%), nasal congestion (18% versus 7%), gastroenteritis (13% versus 2%), and rhinitis (12% versus 0%). </paragraph>
                        <paragraph>Laboratory abnormalities occurring more frequently (at least a 10% increase in per-patient incidence) in pediatric patients compared to adult patients were AST increased (75% versus 55% in adults), ALT increased (69% versus 57% in adults), neutrophil count decrease (59% versus 20% in adults), leukocyte count decrease (46% versus 32% in adults), hyperkalemia (39% versus 16%), glucose decrease (29% versus 13% in adults), and lymphocyte increase (25% versus 1%). Three of the 154 pediatric patients discontinued VITRAKVI due to an adverse reaction associated with a laboratory abnormality (1 patient with Grade 3 increased ALT and 2 patients with Grade 3 decreased neutrophil count).</paragraph>
                        <paragraph>The pharmacokinetics of VITRAKVI in the pediatric population were similar to those seen in adults <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="b52217d1-bacb-4a5b-8e7c-bf1c68e7714b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Juvenile Animal Toxicity Data</paragraph>
                              <paragraph>Larotrectinib was administered in a juvenile toxicity study in rats at twice daily doses of 0.2, 2 and 7.5 mg/kg from postnatal day (PND) 7 to 27 and at twice daily doses of 0.6, 6 and 22.5mg/kg between PND 28 and 70. The dosing period was equivalent to human pediatric populations from newborn to adulthood. The doses of 2/6 mg/kg twice daily [approximately 0.7 times the human exposure (AUC) at the clinical dose of 100 mg twice daily] and 7.5/22.5 mg/kg twice daily (approximately 4 times the human exposure at the clinical dose of 100 mg twice daily) resulted in mortality between PND 9 to 99; a definitive cause of death was not identified in the majority of cases.</paragraph>
                              <paragraph>The main findings were transient central nervous system-related signs including head flick, tremor, and circling in both sexes. An increase in the number of errors in a maze swim test occurred in females at exposures of approximately 4 times the human exposure (AUC) at the clinical dose of 100 mg twice daily. Decreased growth and delays in sexual development occurred in the mid- and high-dose groups. Mating was normal in treated animals, but a reduction in pregnancy rate occurred at the high-dose of 7.5/22.5 mg/kg twice daily (approximately 4 times the human exposure at the clinical dose of 100 mg twice daily).</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="dec0e2de-3e24-45a7-94f3-56c91d9c2372"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of 444 patients in the overall safety population who received VITRAKVI, 20% of patients were ≥ 65 years of age and 6% of patients were ≥ 75 years of age. No overall differences in safety or effectiveness of VITRAKVI were observed between patients 65 years and older and younger adult patients. </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="b82d17cb-38f2-467c-8e72-e59e0ac9a7e2"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A). Larotrectinib clearance was reduced in subjects with moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Reduce VITRAKVI dose as recommended <content styleCode="italics">[see <linkHtml href="#S2.7">Dosage and Administration (2.7)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="13d28065-1d6c-4414-8381-1f20b87329ec"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph>No dose adjustment is recommended for patients with renal impairment of any severity <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="2b3eb3ee-42b0-4ce4-8663-d6bc626d9e96"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Larotrectinib is a kinase inhibitor. VITRAKVI (larotrectinib) capsules and oral solution are formulated using larotrectinib sulfate. The molecular formula for larotrectinib sulfate is C<sub>21</sub>H<sub>24</sub>F<sub>2</sub>N<sub>6</sub>O<sub>6</sub>S and the molecular weight is 526.51 g/mol for the sulfate salt and 428.44 g/mol for the free base. The chemical name is (3<content styleCode="italics">S</content>)-<content styleCode="italics">N</content>-{5-[(2<content styleCode="italics">R</content>)-2-(2,5-difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxy-1-pyrrolidinecarboxamide sulfate. Larotrectinib sulfate has the following chemical structure:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Larotrectinib sulfate is an off-white to pinkish yellow solid that is not hygroscopic. The aqueous solubility of larotrectinib at 37°C is pH dependent (very soluble at pH 1.0 and freely soluble at pH 6.8, according to USP descriptive terms of solubility). </paragraph>
                  <paragraph>VITRAKVI (larotrectinib) capsules and oral solution are for oral use. Each capsule contains 25 mg or 100 mg larotrectinib (30.7 mg and 123 mg larotrectinib sulfate, respectively) in a hard gelatin capsule. The capsule is composed of gelatin, titanium dioxide, and edible ink. </paragraph>
                  <paragraph>The oral solution packaged in one bottle containing 100 mL contains 20 mg/mL larotrectinib (24.6 mg/mL larotrectinib sulfate) and the following inactive ingredients: purified water, hydroxypropyl betadex, sucrose, glycerin, sorbitol, citric acid, sodium phosphate, sodium citrate dihydrate, propylene glycol and flavoring. Preserved with methylparaben and potassium sorbate.</paragraph>
                  <paragraph>The oral solution packaged in two bottles each containing 50 mL contains 20 mg/mL larotrectinib (24.6 mg/mL larotrectinib sulfate) and the following inactive ingredients: purified water, hydroxypropyl betadex, sucralose, sodium citrate, strawberry flavor, and citric acid. Preserved with sodium benzoate.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="a8e4b505-ac6d-49e0-903d-10402ae86704"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="S12.1">
                     <id root="0e13d993-c92a-4b5c-a50d-f05b92c20e82"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Larotrectinib is an inhibitor of the tropomyosin receptor kinases (TRK), TRKA, TRKB, and TRKC. In a broad panel of purified enzyme assays, larotrectinib inhibited TRKA, TRKB, and TRKC with IC<sub>50</sub> values between 5-11 nM. One other kinase TNK2 was inhibited at approximately 100-fold higher concentration. TRKA, B, and C are encoded by the genes <content styleCode="italics">NTRK1, NTRK2,</content> and <content styleCode="italics">NTRK3.</content> Chromosomal rearrangements involving in-frame fusions of these genes with various partners can result in constitutively-activated chimeric TRK fusion proteins that can act as an oncogenic driver, promoting cell proliferation and survival in tumor cell lines. </paragraph>
                        <paragraph>In in vitro and in vivo tumor models, larotrectinib demonstrated anti-tumor activity in cells with constitutive activation of TRK proteins resulting from gene fusions, deletion of a protein regulatory domain, or in cells with TRK protein overexpression. Larotrectinib had minimal activity in cell lines with point mutations in the TRKA kinase domain, including the clinically identified acquired resistance mutation, G595R. Point mutations in the TRKC kinase domain with clinically identified acquired resistance to larotrectinib include G623R, G696A, and F617L. </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="182504bd-14e7-4767-a9bb-d3d91fcce0f9"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="0aa650b8-3431-4256-a456-26746dd89f1d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Cardiac Electrophysiology</paragraph>
                              <paragraph>At a dose 9-fold higher than the recommended adult dose, VITRAKVI does not prolong QTc intervals to any clinically relevant extent.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="7537771f-2f3b-4dfe-b3a1-b3b3e36d3046"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetics of larotrectinib were studied in healthy subjects and adult and pediatric patients with locally advanced or metastatic solid tumors. In healthy subjects who received a single dose of VITRAKVI capsules, systemic exposure (C<sub>max</sub> and AUC) of larotrectinib was dose proportional over the dose range of 100 mg to 400 mg (1 to 4 times the recommended adult dose) and slightly greater than proportional at doses of 600 mg to 900 mg (6 to 9 times the recommended adult dose). In adult patients who received VITRAKVI capsules 100 mg twice daily in Study LOXO-TRK-14001, peak plasma levels (C<sub>max</sub>) of larotrectinib were achieved at approximately 1 hour after dosing and steady-state was reached within 3 days. Mean steady-state larotrectinib [coefficient of variation (CV%)] for C<sub>max</sub> was 788 (81%) ng/mL and AUC<sub>0-24hr</sub> was 4351 (97%) ng*h/mL. </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="1feb172b-5796-4aaf-b76e-5238c83daeda"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Absorption</paragraph>
                              <paragraph>The mean absolute bioavailability of VITRAKVI capsules was 34% (range: 32% to 37%). In healthy subjects, the AUC of VITRAKVI oral solution was similar to that of the capsules and the C<sub>max</sub> was 36% higher with the oral solution. </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="23dc2f8c-5b3f-49d0-ae27-ae92de3cd37d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph styleCode="italics">Effect of Food</paragraph>
                                    <paragraph>The AUC of larotrectinib was similar and the C<sub>max</sub> was reduced by 35% after oral administration of a single 100 mg capsule of VITRAKVI to healthy subjects taken with a high-fat meal (approximately 900 calories, 58 grams carbohydrate, 56 grams fat and 43 grams protein) compared to the C<sub>max</sub> and AUC in the fasted state.</paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="5e993fc0-b717-4930-b45f-fda449488511"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Distribution</paragraph>
                              <paragraph>The mean (CV%) volume of distribution (V<sub>ss</sub>) of larotrectinib is 48 (38%) L following intravenous administration of larotrectinib in healthy subjects. </paragraph>
                              <paragraph>Larotrectinib is 70% bound to human plasma proteins in vitro and binding is independent of drug concentrations. The blood-to-plasma concentration ratio is 0.9.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="26143f1b-40d2-43d6-a832-4db2b74bd211"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Elimination</paragraph>
                              <paragraph>The mean (CV%) clearance (CL/F) of larotrectinib is 98 (44%) L/h and the half-life is 2.9 hours following oral administration of VITRAKVI in healthy subjects. </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="1c2fd1e7-efea-43a8-ae49-609a93194281"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph styleCode="italics">Metabolism</paragraph>
                                    <paragraph>Larotrectinib is metabolized predominantly by CYP3A4. Following oral administration of a single [<sup>14</sup>C] radiolabeled 100 mg dose of larotrectinib to healthy subjects, unchanged larotrectinib constituted 19% and an O-linked glucuronide constituted 26% of the major circulating radioactive drug components in plasma. </paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="a64d79ec-6192-4ecc-8cd3-86aa82ea372e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph styleCode="italics">Excretion</paragraph>
                                    <paragraph>Following oral administration of a single [<sup>14</sup>C] radiolabeled 100 mg dose of larotrectinib to healthy subjects, 58% (5% unchanged) of the administered radioactivity was recovered in feces and 39% (20% unchanged) was recovered in urine. </paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b040fc05-c54a-4d5a-a916-d8f611a42440"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Specific Populations</paragraph>
                              <paragraph>Age (range: 28 days to 82 years), sex, and body weight (range: 3.8 kg to 179 kg) had no clinically meaningful effect on the pharmacokinetics of larotrectinib. </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="80d90c4f-da6d-4073-b579-2ad58b4db57a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph styleCode="italics">Pediatric Patients</paragraph>
                                    <paragraph>In pediatric patients, the larotrectinib geometric mean (%CV) AUC<sub>0-24hr</sub> by age subgroup was: 3348 (66%) ng*h/mL in patients 1 month to &lt; 2 years (n  = 9), 4135 (36%) ng*h/mL in patients 2 to &lt; 12 years (n  = 15), and 3108 (69%) ng*h/mL and in patients 12 to &lt; 18 years (n  = 9).</paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="4e93a7e4-5620-4582-b99b-1dc91757986e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph styleCode="italics">Patients with Renal Impairment </paragraph>
                                    <paragraph>Following oral administration of a single 100 mg dose of VITRAKVI capsules in subjects with end-stage renal disease (e.g., subjects who required dialysis), the AUC<sub>0-INF</sub> of larotrectinib increased 1.5-fold and C<sub>max</sub> increased 1.3-fold as compared to that in subjects with normal renal function (creatinine clearance ≥ 90 mL/min as estimated by Cockcroft-Gault). The pharmacokinetics of VITRAKVI in patients with moderate to severe renal impairment (creatinine clearance ≤ 60 mL/min) have not been studied. </paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="ca6d0d43-158d-4e7a-81ed-1e22e0cdd8f2"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph styleCode="italics">Patients with Hepatic Impairment </paragraph>
                                    <paragraph>Following oral administration of a single 100 mg dose of VITRAKVI capsules, the AUC<sub>0-INF</sub> of larotrectinib increased 1.3-fold in subjects with mild hepatic impairment (Child-Pugh A), 2-fold in subjects with moderate hepatic impairment (Child-Pugh B) and 3.2-fold in subjects with severe hepatic impairment (Child-Pugh C) as compared to that in subjects with normal hepatic function. The C<sub>max</sub> was similar in subjects with mild and moderate hepatic impairment and the C<sub>max</sub> of larotrectinib increased 1.5-fold in subjects with severe hepatic impairment as compared to that in subjects with normal hepatic function <content styleCode="italics">[see <linkHtml href="#S2.7">Dosage and Administration (2.7)</linkHtml>, <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ac1ccd53-0838-4b23-9cd1-a22a002b3037"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Drug Interaction Studies</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="310f257a-5e4f-4c85-b36e-80ccd207fe83"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph styleCode="italics">Clinical Studies</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Effect of CYP3A Inhibitors: </content>Coadministration of a single 100 mg dose of VITRAKVI capsules with itraconazole (strong CYP3A inhibitor) increased the AUC<sub>0-INF</sub> of larotrectinib by 4.3-fold and the C<sub>max</sub> by 2.8-fold as compared to VITRAKVI administered alone <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>, <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>].</content>
                                    </paragraph>
                                    <paragraph>Coadministration of VITRAKVI with fluconazole (moderate CYP3A4 inhibitor) is predicted to increase VITRAKVI steady state AUC by 2.7-fold and C<sub>max</sub> by 1.9-fold.</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Effect of CYP3A Inducers: </content>Coadministration of a single 100 mg dose of VITRAKVI capsules with rifampin (strong CYP3A inducer) decreased the AUC<sub>0-INF</sub> of larotrectinib by 81% and the C<sub>max</sub> by 71% as compared to VITRAKVI administered alone <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>. </paragraph>
                                    <paragraph>Coadministration of VITRAKVI with efavirenz (moderate CYP3A4 inducer) is predicted to decrease steady state AUC of VITRAKVI by approximately 72% and C<sub>max</sub> by 60% compared to VITRAKVI administered alone <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>].</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Strong P-glycoprotein (P-gp) Inhibitors: </content>Coadministration of a single 100 mg dose of VITRAKVI capsules with a P-gp inhibitor (rifampin) increased the AUC<sub>0-INF</sub> of larotrectinib by 1.7-fold and the C<sub>max</sub> by 1.8-fold as compared to VITRAKVI administered alone. </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Larotrectinib on CYP3A4 Substrates:</content> Coadministration of VITRAKVI capsules 100 mg twice daily with a sensitive CYP3A4 substrate (midazolam) increased both the AUC<sub>0-INF</sub> and C<sub>max</sub> of midazolam by 1.7-fold as compared to midazolam administered alone. The AUC<sub>0-INF</sub> and C<sub>max </sub>of 1-hydroxymidazolam, the main metabolite of midazolam, were both increased 1.4-fold as compared to when midazolam was administered alone <content styleCode="italics">[see <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>. </paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="326a29e8-ec79-4e33-b17f-51c137c45dea"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph styleCode="italics">In Vitro Studies</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Transporter on Larotrectinib:</content> Larotrectinib is a substrate for P-gp and BCRP. Larotrectinib is not a substrate of OAT1, OAT3, OCT1, OCT2, OATP1B1, or OATP1B3.</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Larotrectinib on Transporters:</content> Larotrectinib is not an inhibitor of BCRP, P-gp, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, BSEP, MATE1 and MATE2-K at clinically relevant concentrations.</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Larotrectinib on CYP Substrates: </content>Larotrectinib is not an inhibitor or inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 at clinically relevant concentrations.</paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="710ee85b-2561-43f3-9e22-d30254697635"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="S13.1">
                     <id root="ffa833e2-53a2-4324-9bd0-0b3f6325b3f2"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Carcinogenicity studies have not been conducted with larotrectinib. Larotrectinib was not mutagenic in the in vitro bacterial reverse mutation (Ames) assays, with or without metabolic activation, or in the in vitro mammalian mutagenesis assays, with or without metabolic activation. In vivo, larotrectinib was negative in the mouse micronucleus test.</paragraph>
                        <paragraph>Fertility studies with larotrectinib have not been conducted. In a 3-month repeat-dose toxicity study in the rat, larotrectinib had no effects on spermatogenesis at 75 mg/kg/day (approximately 7 times the human exposure at the 100 mg twice daily dose). Additionally, larotrectinib had no histological effects on the male reproductive tract in rats or monkeys at doses resulting in exposures up to 10 times the human exposure (AUC<sub>0-24hr</sub>) at the 100 mg twice daily clinical dose. </paragraph>
                        <paragraph>In a 1-month repeat-dose study in the rat, decreased uterine weight and uterine atrophy were seen at 200 mg/kg/day [approximately 45 times the human exposure (AUC) at the 100 mg twice daily dose]. Fewer corpora lutea and increased incidence of anestrus were also noted at doses ≥ 60 mg/kg/day (approximately 10 times the human exposure at the 100 mg twice daily dose). Decreased fertility occurred in a juvenile animal study <content styleCode="italics">[see <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>].</content> There were no findings in female reproductive organs in repeat-dose studies in monkeys at exposures up to 22 times the human exposure at the 100 mg twice daily dose.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="bb1bdf11-06a7-42f3-b536-6fbc20a64cb3"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>In general toxicology studies conducted in rats and monkeys and in reproductive toxicology studies conducted in rats and rabbits, administration of larotrectinib led to increased food consumption and increased body weight at doses resulting in exposures 0.6 times the human exposure at the 100 mg twice daily clinical dose. Obesity has also been one phenotypic outcome of some human syndromes resulting from congenital mutations in <content styleCode="italics">NTRK2</content> resulting in altered TRK signaling. </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="7217c7fa-65cd-4346-8c88-4d5e1321def8"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of VITRAKVI was evaluated in pediatric and adult patients with unresectable or metastatic solid tumors with a <content styleCode="italics">NTRK</content> gene fusion enrolled in one of three multicenter, open-label, single-arm clinical trials: Study LOXO-TRK-14001 (NCT02122913), SCOUT (NCT02637687), and NAVIGATE (NCT02576431). All patients were required to have progressed following systemic therapy for their disease, if available, or would have required surgery with significant morbidity for locally advanced disease.</paragraph>
                  <paragraph>Adult patients received VITRAKVI 100 mg orally twice daily and pediatric patients (18 years or younger) received VITRAKVI 100 mg/m<sup>2</sup> up to a maximum dose of 100 mg orally twice daily until unacceptable toxicity or disease progression. Identification of positive <content styleCode="italics">NTRK</content> gene fusion status was prospectively determined in local laboratories using next generation sequencing (NGS) (89%), fluorescence in situ hybridization (FISH) or reverse transcription polymerase chain reaction (RT-PCR). <content styleCode="italics">NTRK</content> gene fusions were inferred in 14 patients who had a documented <content styleCode="italics">ETV6 or NTRK 3</content> translocation identified by FISH. The major efficacy outcome measures were overall response rate (ORR) and duration of response (DOR), as determined by a blinded independent review committee (BIRC) according to RECIST v1.1.</paragraph>
                  <paragraph>The assessment of efficacy was based on 339 patients with solid tumors with an <content styleCode="italics">NTRK</content> gene fusion enrolled across the three clinical trials. Baseline characteristics were: median age 38 years (range: 18 days to 90 years); 39% &lt;18 years of age; 51% female; 57% White, 28% Asian, 2.4% Black or African American; 6% Hispanic or Latino and ECOG performance status (PS) 0-1 (88%) or 2 (10%). Sixty-three percent of patients had metastatic disease, including patients with brain metastases, and 22% had locally advanced, unresectable disease. Ninety-two percent of patients had received prior treatment for their cancer, including surgery, radiotherapy, or systemic therapy, including RAI. Seventy percent of all patients had received prior systemic therapy in the unresectable or metastatic setting excluding RAI; 30% were treatment naive, 33% had received 1 prior therapy and 37% percent had received 2 or more prior therapies with a median of one prior systemic regimen. </paragraph>
                  <paragraph>Efficacy results are summarized in Tables 5, 6, and 7.</paragraph>
                  <table width="80%">
                     <caption>Table 5 	Efficacy Results for Patients with Solid Tumors Harboring NTRK Gene Fusions</caption>
                     <col width="50%" align="left" valign="middle"/>
                     <col width="50%" align="center" valign="middle"/>
                     <thead>
                        <tr styleCode="botrule">
                           <th styleCode="Lrule Rrule">Efficacy Parameter</th>
                           <th styleCode="Rrule">VITRAKVI <br/> N = 339</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="2">+ Denotes ongoing response.</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Overall response rate</content> (95% CI)</td>
                           <td styleCode="Rrule">60% (55%, 65%)</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">   Complete response rate</td>
                           <td styleCode="Rrule">24%<footnote>5% were pathological complete response. Patients undergoing a surgical resection whose post-operative pathologic assessment showed no viable tumor cells and negative margins were pathological complete responders provided that no other sites of disease were present.</footnote>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">   Partial response rate</td>
                           <td styleCode="Rrule">36%</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule bold">Duration of response (DOR)</td>
                           <td styleCode="Rrule bold">N = 204</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">   Median (months) (95% CI)</td>
                           <td styleCode="Rrule">43.3<footnote>Kaplan-Meier estimates</footnote> (32.5, NE<footnote>NE: Not evaluable </footnote>)</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">   Range (months)</td>
                           <td styleCode="Rrule">0.0+, 73.7+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">   % with Observed DOR&gt; 12 months</td>
                           <td styleCode="Rrule">64% </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">   % with Observed DOR&gt; 24 months</td>
                           <td styleCode="Rrule">45%</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="80%">
                     <caption>Table 6	 Efficacy Results by Tumor Type</caption>
                     <col width="20%" align="left" valign="middle"/>
                     <col width="20%" align="center" valign="middle"/>
                     <col width="20%" align="center" valign="middle"/>
                     <col width="20%" align="center" valign="middle"/>
                     <col width="20%" align="center" valign="middle"/>
                     <thead>
                        <tr styleCode="botrule">
                           <th styleCode="Lrule Rrule" valign="bottom" rowspan="2">Tumor Type</th>
                           <th styleCode="Rrule" rowspan="2">Patients  <br/> (N=339)</th>
                           <th styleCode="Rrule" colspan="2">ORR</th>
                           <th styleCode="Rrule" rowspan="2">DOR <br/> Range (months)</th>
                        </tr>
                        <tr>
                           <th styleCode="Rrule" align="center">%</th>
                           <th styleCode="Rrule">95% CI</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="5">NA = not applicable due to small numbers or lack of response; NE = not evaluable; SD = stable disease; PD = progressive disease. <br/> + Denotes ongoing response.</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Soft tissue sarcoma</td>
                           <td styleCode="Rrule">70</td>
                           <td styleCode="Rrule">70%</td>
                           <td styleCode="Rrule">(58%, 80%)</td>
                           <td styleCode="Rrule">0.0+, 72.7+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Infantile fibrosarcoma</td>
                           <td styleCode="Rrule">49</td>
                           <td styleCode="Rrule">94%</td>
                           <td styleCode="Rrule">(83%, 99%)</td>
                           <td styleCode="Rrule">1.6+, 73.7+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Primary CNS</td>
                           <td styleCode="Rrule">49</td>
                           <td styleCode="Rrule">27%</td>
                           <td styleCode="Rrule">(15%, 41%)</td>
                           <td styleCode="Rrule">1.9+, 57.5+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Lung</td>
                           <td styleCode="Rrule">30</td>
                           <td styleCode="Rrule">70%</td>
                           <td styleCode="Rrule">(51%, 85%)</td>
                           <td styleCode="Rrule">1.9+, 56.2+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Thyroid</td>
                           <td styleCode="Rrule">30</td>
                           <td styleCode="Rrule">63%</td>
                           <td styleCode="Rrule">(44%, 80%)</td>
                           <td styleCode="Rrule">3.7, 72.4+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">   Differentiated</td>
                           <td styleCode="Rrule">23</td>
                           <td styleCode="Rrule">78%</td>
                           <td styleCode="Rrule">(56%, 93%)</td>
                           <td styleCode="Rrule">4.9, 72.4+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">   Non-differentiated</td>
                           <td styleCode="Rrule">7</td>
                           <td styleCode="Rrule">14%</td>
                           <td styleCode="Rrule">(0%, 58%)</td>
                           <td styleCode="Rrule">3.7<footnote ID="t61">Observed values at data cutoff, not a range.</footnote>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Salivary gland</td>
                           <td styleCode="Rrule">25</td>
                           <td styleCode="Rrule">84%</td>
                           <td styleCode="Rrule">(64%, 95%)</td>
                           <td styleCode="Rrule">7.4, 65.2+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">   MASC</td>
                           <td styleCode="Rrule">14</td>
                           <td styleCode="Rrule">79%</td>
                           <td styleCode="Rrule">(49%, 95%)</td>
                           <td styleCode="Rrule">7.7, 59.1</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Colorectal<footnote>Colorectal Tumor Type includes 23 colon cancers and 1 rectal cancer.</footnote>
                           </td>
                           <td styleCode="Rrule">24</td>
                           <td styleCode="Rrule">46%</td>
                           <td styleCode="Rrule">(26%, 67%)</td>
                           <td styleCode="Rrule">3.9, 45.2+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Breast</td>
                           <td styleCode="Rrule">14</td>
                           <td styleCode="Rrule">57%</td>
                           <td styleCode="Rrule">(29%, 82%)</td>
                           <td styleCode="Rrule">7.4, 58.2+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">   Secretory</td>
                           <td styleCode="Rrule">6</td>
                           <td styleCode="Rrule">83%</td>
                           <td styleCode="Rrule">(36%, 100%)</td>
                           <td styleCode="Rrule">11.1, 58.2+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">   Non-secretory</td>
                           <td styleCode="Rrule">8</td>
                           <td styleCode="Rrule">38%</td>
                           <td styleCode="Rrule">(9%, 76%)</td>
                           <td styleCode="Rrule">7.4, 12.5+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Melanoma</td>
                           <td styleCode="Rrule">11</td>
                           <td styleCode="Rrule">45%</td>
                           <td styleCode="Rrule">(17%, 77%)</td>
                           <td styleCode="Rrule">1.9+, 23.2+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Pancreas</td>
                           <td styleCode="Rrule">7</td>
                           <td styleCode="Rrule">14%</td>
                           <td styleCode="Rrule">(0%, 58%)</td>
                           <td styleCode="Rrule">5.8<footnoteRef IDREF="t61"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Gastrointestinal stromal tumor</td>
                           <td styleCode="Rrule">5</td>
                           <td styleCode="Rrule">80%</td>
                           <td styleCode="Rrule">(28%, 99%)</td>
                           <td styleCode="Rrule">9.5, 50.4+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Cholangiocarcinoma</td>
                           <td styleCode="Rrule">4</td>
                           <td styleCode="Rrule">2 SD, 2 NE </td>
                           <td styleCode="Rrule">NA</td>
                           <td styleCode="Rrule">NA</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Bone sarcoma</td>
                           <td styleCode="Rrule">3</td>
                           <td styleCode="Rrule">33%</td>
                           <td styleCode="Rrule">(1%, 91%)</td>
                           <td styleCode="Rrule">9.5<footnoteRef IDREF="t61"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Gastric</td>
                           <td styleCode="Rrule">3</td>
                           <td styleCode="Rrule">2 PD, NE</td>
                           <td styleCode="Rrule">NA</td>
                           <td styleCode="Rrule">NA</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Cancer of unknown primary</td>
                           <td styleCode="Rrule">2</td>
                           <td styleCode="Rrule">100%</td>
                           <td styleCode="Rrule">(16%, 100%)</td>
                           <td styleCode="Rrule">5.6, 7.4</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Congenital mesoblastic nephroma</td>
                           <td styleCode="Rrule">2</td>
                           <td styleCode="Rrule">100%</td>
                           <td styleCode="Rrule">(16%, 100%)</td>
                           <td styleCode="Rrule">32.9, 44.5</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Prostate</td>
                           <td styleCode="Rrule">2</td>
                           <td styleCode="Rrule">SD, PD</td>
                           <td styleCode="Rrule">NA</td>
                           <td styleCode="Rrule">NA</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Appendix</td>
                           <td styleCode="Rrule">1</td>
                           <td styleCode="Rrule">SD</td>
                           <td styleCode="Rrule">NA</td>
                           <td styleCode="Rrule">NA</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Cervix</td>
                           <td styleCode="Rrule">1</td>
                           <td styleCode="Rrule">SD</td>
                           <td styleCode="Rrule">NA</td>
                           <td styleCode="Rrule">NA</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Duodenal</td>
                           <td styleCode="Rrule">1</td>
                           <td styleCode="Rrule">PD</td>
                           <td styleCode="Rrule">NA</td>
                           <td styleCode="Rrule">NA</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Esophageal</td>
                           <td styleCode="Rrule">1</td>
                           <td styleCode="Rrule">PD</td>
                           <td styleCode="Rrule">NA</td>
                           <td styleCode="Rrule">NA</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">External auditory canal</td>
                           <td styleCode="Rrule">1</td>
                           <td styleCode="Rrule">100%</td>
                           <td styleCode="Rrule">(3%, 100%)</td>
                           <td styleCode="Rrule">33.8+<footnoteRef IDREF="t61"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Hepatic</td>
                           <td styleCode="Rrule">1</td>
                           <td styleCode="Rrule">NE</td>
                           <td styleCode="Rrule">NA</td>
                           <td styleCode="Rrule">NA</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Thymus</td>
                           <td styleCode="Rrule">1</td>
                           <td styleCode="Rrule">PD</td>
                           <td styleCode="Rrule">NA</td>
                           <td styleCode="Rrule">NA</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Urothelial</td>
                           <td styleCode="Rrule">1</td>
                           <td styleCode="Rrule">PD</td>
                           <td styleCode="Rrule">NA</td>
                           <td styleCode="Rrule">NA</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Uterus</td>
                           <td styleCode="Rrule">1</td>
                           <td styleCode="Rrule">NE</td>
                           <td styleCode="Rrule">NA</td>
                           <td styleCode="Rrule">NA</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>The ORR for patients with <content styleCode="italics">NTRK1</content> fusions (n=142) was 59% (95% CI: 51, 67), <content styleCode="italics">NTRK2</content> fusions (n=44) was 32% (95% CI: 19, 48) and <content styleCode="italics">NTRK3</content> fusions (n=142) was 67% (95% CI: 59, 75). </paragraph>
                  <table width="80%">
                     <caption>Table 7 	Efficacy Results by NTRK Fusion Partner </caption>
                     <col width="20%" align="left" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <thead>
                        <tr styleCode="botrule">
                           <th styleCode="Lrule Rrule" valign="bottom" rowspan="2">
                              <content styleCode="bold italics">NTRK</content> Partner<footnote>Includes fusion partners which are represented by 3 or more patients in the efficacy analysis set. Does not represent all potential fusion partners. </footnote>
                           </th>
                           <th styleCode="Rrule" valign="bottom" rowspan="2">Patients <br/> (N=339)</th>
                           <th styleCode="Rrule" valign="bottom" colspan="2">ORR</th>
                           <th styleCode="Rrule" valign="bottom" rowspan="2">DOR Range <br/> (months)</th>
                        </tr>
                        <tr>
                           <th styleCode="Rrule" valign="bottom" align="center">%</th>
                           <th styleCode="Rrule" valign="bottom">95% CI</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="5">PD = progressive disease; SD = stable disease; NA = not applicable. <br/> + Denotes ongoing response.</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">ETV6-NTRK3</td>
                           <td styleCode="Rrule">102</td>
                           <td styleCode="Rrule">80% </td>
                           <td styleCode="Rrule">(71%, 88%)</td>
                           <td styleCode="Rrule">0.0+, 66.7+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">TPM3-NTRK1</td>
                           <td styleCode="Rrule">63</td>
                           <td styleCode="Rrule">67%</td>
                           <td styleCode="Rrule">(54%, 78%)</td>
                           <td styleCode="Rrule">0.8+, 73.7+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">LMNA-NTRK1</td>
                           <td styleCode="Rrule">29</td>
                           <td styleCode="Rrule">69%</td>
                           <td styleCode="Rrule">(49%, 85%)</td>
                           <td styleCode="Rrule">3.4, 70.7+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">Inferred ETV6-NTRK3</td>
                           <td styleCode="Rrule">14</td>
                           <td styleCode="Rrule">93%</td>
                           <td styleCode="Rrule">(66%, 100%)</td>
                           <td styleCode="Rrule">1.6+, 73.4+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">TPR-NTRK1</td>
                           <td styleCode="Rrule">10</td>
                           <td styleCode="Rrule">60%</td>
                           <td styleCode="Rrule">(26%, 88%)</td>
                           <td styleCode="Rrule">3.0+, 38.7+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">EML4-NTRK3</td>
                           <td styleCode="Rrule">6</td>
                           <td styleCode="Rrule">50%</td>
                           <td styleCode="Rrule">(12%, 88%)</td>
                           <td styleCode="Rrule">7.9, 40.7+</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">IRF2BP2-NTRK1</td>
                           <td styleCode="Rrule">4</td>
                           <td styleCode="Rrule">100%</td>
                           <td styleCode="Rrule">(40%, 100%)</td>
                           <td styleCode="Rrule">3.7, 47.8+ </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">BCR-NTRK2</td>
                           <td styleCode="Rrule">3</td>
                           <td styleCode="Rrule">67%</td>
                           <td styleCode="Rrule">(9%, 99%)</td>
                           <td styleCode="Rrule">9.2+, 11.0 </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">GKAP1-NTRK2</td>
                           <td styleCode="Rrule">3</td>
                           <td styleCode="Rrule">2 SD, 1 PD</td>
                           <td styleCode="Rrule">NA</td>
                           <td styleCode="Rrule">NA </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">NACC2-NTRK2</td>
                           <td styleCode="Rrule">3</td>
                           <td styleCode="Rrule">33%</td>
                           <td styleCode="Rrule">(1%, 91%)</td>
                           <td styleCode="Rrule">3.7<footnote>Observed values at data cutoff, not a range.</footnote>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">RBPMS-NTRK3</td>
                           <td styleCode="Rrule">3</td>
                           <td styleCode="Rrule">67%</td>
                           <td styleCode="Rrule">(9%, 99%)</td>
                           <td styleCode="Rrule">3.3+, 23.0 </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">SQSTM1-NTRK1</td>
                           <td styleCode="Rrule">3</td>
                           <td styleCode="Rrule">67%</td>
                           <td styleCode="Rrule">(9%, 99%)</td>
                           <td styleCode="Rrule">9.9, 12.9+</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="5d77f7c4-07c9-4267-b99b-d97e77b8cf35"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section>
                     <id root="9fd477a4-4cc6-49d9-af5d-5bad854a1ba8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph styleCode="underline">Capsules</paragraph>
                        <paragraph>25 mg: Hard gelatin opaque white capsule size #2 with blue printing of "BAYER" cross and "25 mg" on the body of the capsule.</paragraph>
                        <table width="50%" styleCode="Noautorules">
                           <col width="50%" align="left" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <list listType="unordered" styleCode="disc">
                                       <item>60 count bottle</item>
                                    </list>
                                 </td>
                                 <td>NDC# 50419-390-01</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>100 mg: Hard gelatin opaque white capsule size #0 with blue printing of "BAYER" cross and "100 mg" on the body of the capsule.</paragraph>
                        <table width="50%" styleCode="Noautorules">
                           <col width="50%" align="left" valign="top"/>
                           <col width="50%" align="left" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <list listType="unordered" styleCode="disc">
                                       <item>60 count bottle</item>
                                    </list>
                                 </td>
                                 <td>NDC# 50419-391-01</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c285c3a5-61ac-4527-b2b1-1e2b6e88a4cc"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store capsules at room temperature 20°C to 25°C (68°F to 77°F); temperature excursions between 15°C and 30°C (59°F to 86°F) are permitted [see USP Controlled Room Temperature]. </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="9ac5f10f-c95e-4b5e-b20e-5e8d1e2a7f93"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Oral Solution Packaged in One Bottle Containing 100 mL </paragraph>
                              <paragraph>20 mg/mL: Clear yellow to orange solution.</paragraph>
                              <table width="50%" styleCode="Noautorules">
                                 <col width="50%" align="left" valign="top"/>
                                 <col width="50%" align="left" valign="top"/>
                                 <tbody>
                                    <tr>
                                       <td>
                                          <list listType="unordered" styleCode="disc">
                                             <item>One bottle containing 100 mL</item>
                                          </list>
                                       </td>
                                       <td>NDC# 50419-392-01</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Refrigerate oral solution at 2°C to 8°C (36°F to 46°F). Do not freeze. </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3c6cb764-6fd7-4c85-80ca-09aa2ad669ba"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph styleCode="underline">Oral Solution Packaged in Two Bottles Each Containing 50 mL</paragraph>
                              <paragraph>20 mg/mL: Colorless to yellow or orange or red or brownish solution.</paragraph>
                              <table width="50%" styleCode="Noautorules">
                                 <col width="50%" align="left" valign="top"/>
                                 <col width="50%" align="left" valign="top"/>
                                 <tbody>
                                    <tr>
                                       <td>
                                          <list listType="unordered" styleCode="disc">
                                             <item>Two bottles each containing 50 mL </item>
                                          </list>
                                       </td>
                                       <td>NDC# 50419-393-03</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Refrigerate oral solution at 2°C to 8°C (36°F to 46°F). Do not freeze.  </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="24f73928-f64c-4473-9973-70ee06c21694"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <section>
                     <id root="9575cded-5d14-4db6-8099-ce820b066d5f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph styleCode="underline">Central Nervous System Effects</paragraph>
                        <paragraph>Advise patients to notify their healthcare provider if they experience new or worsening neurotoxicity. Advise patients not to drive or operate hazardous machinery if they are experiencing neurologic adverse reactions <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="dc946a40-e85d-4edb-a365-9c25068f08be"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph styleCode="underline">Skeletal Fractures</paragraph>
                        <paragraph>Inform patients that bone fractures can occur in patients taking VITRAKVI. Advise patients to report symptoms such as pain, changes in mobility, or deformity to their healthcare provider <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b5f51109-c1fa-485d-bbf0-fc4fc6322c3c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph styleCode="underline">Hepatotoxicity</paragraph>
                        <paragraph>Advise patients that they will need to undergo laboratory tests to monitor liver function <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="899da108-1cea-4197-a7d5-bcbba22d5bcc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph styleCode="underline">Embryo-Fetal Toxicity</paragraph>
                        <paragraph>Advise males and females of reproductive potential of the potential risk to a fetus <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>, <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy and to use effective contraception during the treatment with VITRAKVI and for 1 week after the last dose <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment with VITRAKVI and for 1 week after the last dose <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c261baf8-c675-4cfc-9677-2660649210de"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph styleCode="underline">Lactation</paragraph>
                        <paragraph>Advise women not to breastfeed during treatment with VITRAKVI and for 1 week following the last dose <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="eadc5e07-bf95-4e53-9bc7-b21093a889cb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph styleCode="underline">Infertility</paragraph>
                        <paragraph>Advise females of reproductive potential that VITRAKVI may impair fertility <content styleCode="italics">[See <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b3c296fa-271b-440f-a1a5-50f85664a479"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph styleCode="underline">Drug Interactions</paragraph>
                        <paragraph>Advise patients and caregivers to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products. Inform patients to avoid St. John's wort, grapefruit or grapefruit juice while taking VITRAKVI <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1, </linkHtml>
                              <linkHtml href="#S7.2">7.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="c0a2826c-74a7-4956-a752-9a7ba7c8320b"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section>
               <id root="bdb29c84-4e55-42d7-9fa4-4ac784c9bfe0"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="4%" align="left" valign="top"/>
                     <col width="32%" align="center" valign="top"/>
                     <col width="30%" align="center" valign="top"/>
                     <col width="28%" align="center" valign="top"/>
                     <col width="6%" align="right" valign="top"/>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="3">This Patient Information has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right" colspan="2">Revised: 4/2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule bold" colspan="5" align="center">PATIENT INFORMATION </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule" align="center" colspan="2">VITRAKVI (vi trak vee) <br/> (larotrectinib) <br/> capsules</td>
                           <td/>
                           <td styleCode="Rrule" align="center" colspan="2">VITRAKVI (vi trak vee) <br/> (larotrectinib) <br/> oral solution</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">What is VITRAKVI?</content>
                              <br/>									VITRAKVI is a prescription medicine that is used to treat adults and children with solid tumors (cancer) that: 									<list listType="unordered" styleCode="disc">
                                 <item>are caused by certain abnormal neurotrophic receptor tyrosine kinase (<content styleCode="italics">NTRK)</content> genes <content styleCode="bold">and</content>
                                 </item>
                                 <item>have spread or if surgery to remove their cancer is likely to cause severe complications, <content styleCode="bold">and</content>
                                 </item>
                                 <item>there is no acceptable treatment option <content styleCode="bold">or</content> the cancer grew or spread on other treatment. </item>
                              </list>Your healthcare provider will perform a test to make sure that VITRAKVI is right for you.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">Before taking VITRAKVI, tell your healthcare provider about all of your medical conditions, including if you:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td styleCode="Rrule" colspan="4" align="left" valign="top">
                              <list listType="unordered" styleCode="disc">
                                 <item>have liver problems</item>
                                 <item>have nervous system (neurological) problems</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <list listType="unordered" styleCode="disc">
                                 <item>are pregnant or plan to become pregnant. VITRAKVI can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with VITRAKVI or think you may be pregnant.<br/>
                                    <content styleCode="bold">Females who are able to become pregnant:</content>
                                    <list listType="unordered" styleCode="circle">
                                       <item>Your healthcare provider may do a pregnancy test before you start treatment with VITRAKVI.</item>
                                       <item>You should use effective birth control (contraception) during treatment and for <content styleCode="bold">1 week</content> after the last dose of VITRAKVI. Talk to your healthcare provider about birth control methods that may be right for you.</item>
                                    </list>
                                    <content styleCode="bold">Males with female partners who are able to become pregnant:</content>
                                    <list listType="unordered" styleCode="circle">
                                       <item>You should use effective birth control during treatment with VITRAKVI and for <content styleCode="bold">1 week</content> after the last dose of VITRAKVI.</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if VITRAKVI passes into your breast milk. Do not breastfeed during treatment and for 1 week after the last dose of VITRAKVI.<br/>
                                 </item>
                              </list>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. <br/>Taking VITRAKVI with certain other medicines may affect the amount of VITRAKVI or other medicines in your blood and may cause side effects or affect the way that VITRAKVI works. <br/>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">How should I take VITRAKVI?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Take VITRAKVI exactly as your healthcare provider tells you.</item>
                                 <item>Do not change your dose or stop taking VITRAKVI unless your healthcare provider tells you.</item>
                                 <item>VITRAKVI comes in capsules and as an oral solution. </item>
                                 <item>If your healthcare provider prescribes VITRAKVI oral solution: 									<list listType="unordered" styleCode="circle">
                                       <item>Your healthcare provider will provide you with the VITRAKVI oral solution, oral syringes and bottle adaptors or send you to a pharmacy that can provide you with VITRAKVI oral solution, oral syringes and bottle adaptors. </item>
                                       <item>Your healthcare provider should show you how to correctly measure and give a dose of VITRAKVI oral solution. </item>
                                       <item>See the detailed <linkHtml href="#IFU">Instructions for Use</linkHtml> that comes with VITRAKVI oral solution for information about the correct way to measure and give a dose of VITRAKVI oral solution. If you have any questions, talk to your healthcare provider or pharmacist.</item>
                                    </list>
                                 </item>
                                 <item>VITRAKVI is usually taken by mouth 2 times a day.</item>
                                 <item>Swallow VITRAKVI capsules whole with water. Do not chew or crush the capsules.</item>
                                 <item>Take VITRAKVI with or without food.</item>
                                 <item>If you vomit after taking a dose of VITRAKVI, wait and take the next dose at your scheduled time.</item>
                                 <item>If you miss a dose of VITRAKVI, take it as soon as you remember. If your next scheduled dose is due within 6 hours, skip the missed dose and take your next dose at your regularly scheduled time.</item>
                                 <item>If you take too much VITRAKVI, call your healthcare provider or go to the nearest hospital emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">What should I avoid while taking VITRAKVI?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>VITRAKVI can make you feel dizzy. Do not drive or operate machinery until you know how VITRAKVI affects you.</item>
                                 <item>Avoid taking St. John's wort, eating grapefruit, or drinking grapefruit juice during treatment with VITRAKVI.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">What are the possible side effects of VITRAKVI?</content>
                              <br/>
                              <content styleCode="bold">VITRAKVI may cause serious side effects, including:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Central nervous system (CNS) problems</content>. VITRAKVI may cause dizziness, confusion, problems with concentration, attention, and memory, changes in your mood, and sleep problems. Tell your healthcare provider if you develop any of these symptoms or they get worse. </item>
                                 <item>
                                    <content styleCode="bold">Bone fractures</content>. Bone fractures can happen with VITRAKVI. Tell your healthcare provider if you develop pain, changes in your ability to move around, or bone abnormalities. </item>
                                 <item>
                                    <content styleCode="bold">Liver problems</content>. Abnormal liver blood tests may occur with VITRAKVI and can sometimes become serious. Your healthcare provider will do blood tests to check your liver function before starting and during treatment with VITRAKVI as needed. Tell your healthcare provider right away if you develop new or worsening symptoms of liver problems including: 									</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="circle">
                                 <item>yellowing of your skin or the white part of your eyes (jaundice)</item>
                                 <item>dark or brown urine</item>
                                 <item>pain in the upper right side of your stomach area (abdomen)</item>
                              </list>
                           </td>
                           <td colspan="3" styleCode="Rrule" align="left" valign="top">
                              <list listType="unordered" styleCode="circle">
                                 <item>bruising or bleeding more easily than normal</item>
                                 <item>tiredness</item>
                                 <item>nausea or vomiting</item>
                                 <item>loss of appetite</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">Your healthcare provider may decrease your dose, temporarily stop or permanently stop your treatment with VITRAKVI if you develop serious side effects.<br/>
                              <content styleCode="bold">The most common side effects of VITRAKVI include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="disc">
                                 <item>increase in certain liver blood tests </item>
                                 <item>low red blood cell and white blood cell counts </item>
                                 <item>low levels of protein called albumin in the blood </item>
                                 <item>muscle and bone pain </item>
                                 <item>increased levels of enzyme called alkaline phosphatase in the blood (test for liver or bone problems) </item>
                                 <item>low levels of calcium in the blood </item>
                                 <item>tiredness </item>
                                 <item>vomiting </item>
                              </list>
                           </td>
                           <td styleCode="Rrule" colspan="3" align="left" valign="top">
                              <list listType="unordered" styleCode="disc">
                                 <item>cough </item>
                                 <item>constipation </item>
                                 <item>fever </item>
                                 <item>diarrhea </item>
                                 <item>nausea </item>
                                 <item>stomach (abdomen) pain </item>
                                 <item>dizziness </item>
                                 <item>rash </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="5">VITRAKVI may affect fertility in females and may affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you.<br/>								These are not all the possible side effects with VITRAKVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. 									</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">How should I store VITRAKVI?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Store VITRAKVI capsules at room temperature between 68˚F to 77˚F (20˚C to 25˚C).</item>
                                 <item>Store VITRAKVI oral solution in the refrigerator between 36° F to 46° F (2° C to 8° C).  Do not freeze. </item>
                                 <item>Throw away (dispose of) any unused VITRAKVI oral solution: 									<list listType="unordered" styleCode="circle">
                                       <item>Bottle of 100 mL: remaining 90 days after first opening the bottle</item>
                                       <item>Bottle of 50 mL: remaining 31 days after first opening the bottle</item>
                                    </list>
                                 </item>
                              </list>
                              <content styleCode="bold">Keep VITRAKVI and all medicines out of the reach of children</content>. 									</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">General information about the safe and effective use of VITRAKVI.</content>
                              <br/>									Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VITRAKVI for a condition for which it was not prescribed. Do not give VITRAKVI to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for more information about VITRAKVI that is written for health professionals. 									</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">What are the ingredients in VITRAKVI?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient</content>: larotrectinib<br/>
                              <content styleCode="bold">Inactive ingredients</content>:<br/>								Capsule: gelatin, titanium dioxide and edible ink<br/>								Oral Solution Packaged in One Bottle Containing 100 mL: purified water, hydroxypropyl betadex, sucrose, glycerin, sorbitol, citric acid, sodium phosphate, sodium citrate dihydrate, propylene glycol and flavoring. Preserved with methylparaben and potassium sorbate.<br/>								Oral Solution Packaged in Two Bottles Each Containing 50 mL: purified water, hydroxypropyl betadex, sucralose, sodium citrate, strawberry flavor, and citric acid. Preserved with sodium benzoate.<br/>								Manufactured for Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981 <br/> For more information, go to www.VITRAKVI.com or call 1-888-842-2937 									</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="IFU">
               <id root="4ea9bef2-d7d8-489e-a593-d5d09fec8315"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="30%" align="left" valign="top"/>
                     <col width="70%" align="left" valign="top"/>
                     <thead>
                        <tr styleCode="botrule">
                           <th styleCode="Lrule Rrule" colspan="2" align="center">INSTRUCTIONS FOR USE <br/> VITRAKVI (vi trak vee) <br/> (larotrectinib)  <br/> oral solution</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>Read this Instructions for Use before you take or give a dose of VITRAKVI oral solution for the first time and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.</paragraph>
                              <paragraph>Your healthcare provider should show you how to correctly measure the prescribed dose of VITRAKVI oral solution before you take or give a dose for the first time.</paragraph>
                              <paragraph styleCode="bold">Important information about measuring VITRAKVI oral solution:</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Always use the oral syringes provided with VITRAKVI to make sure that you correctly measure the prescribed dose. </item>
                                 <item>When you receive VITRAKVI oral solution from your healthcare provider or pharmacist, you will get a box that contains VITRAKVI oral solution. You may receive more than 1 box of VITRAKVI oral solution.</item>
                                 <item>Your healthcare provider or pharmacist will also provide you bottle adaptors and syringes. You will receive one bottle adaptor per bottle of VITRAKVI oral solution. After inserting the bottle adaptor into the bottle, <content styleCode="bold">do not</content> remove the bottle adaptor.</item>
                                 <item>You will receive five 1 mL or 5 mL oral syringes that are marked to help you correctly measure the prescribed dose of VITRAKVI oral solution. Each oral syringe may be used over a 7-day period. <content styleCode="bold">Do not</content> use a household teaspoon to measure the dose.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="center">
                              <paragraph styleCode="bold">Supplies needed to take or give a dose of VITRAKVI oral solution</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="center">
                              <paragraph styleCode="bold" ID="figurea">Figure A</paragraph>
                              <renderMultiMedia referencedObject="MM2"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule bold" colspan="2">
                              <paragraph>How to prepare a dose of VITRAKVI oral solution:</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 1: </content>Remove the VITRAKVI oral solution bottle from the box. Place the bottle on a flat work surface. Open the bottle by pushing down firmly on the child-resistant cap and turning it in the direction of the arrow (counter-clockwise) <content styleCode="bold">See <linkHtml href="#figureb">Figure B</linkHtml>
                                 </content>. <content styleCode="bold">Do not</content> throw away the child-resistant cap. </paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figureb">Figure B</paragraph>
                              <renderMultiMedia referencedObject="MM3"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 2: </content>Insert the bottle adaptor by pressing it into the bottle neck and make sure it is secure. <content styleCode="bold">See <linkHtml href="#figurec">Figure C</linkHtml>
                                 </content>. <content styleCode="bold">Do not</content> remove the bottle adaptor. If the bottle adaptor is missing, talk to your healthcare provider.</paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figurec">Figure C</paragraph>
                              <renderMultiMedia referencedObject="MM4"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 3:</content> Remove the oral syringe from the wrapper. Throw the wrapper away in your household trash. Look at the markings on the barrel of the oral syringe and find the marking that matches the VITRAKVI oral solution dose in mL prescribed by your healthcare provider. <content styleCode="bold">See <linkHtml href="#figured">Figure D</linkHtml>
                                 </content>.</paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figured">Figure D</paragraph>
                              <renderMultiMedia referencedObject="MM5"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 4:</content> With the bottle on your flat work surface, use 1 hand to hold the bottle upright. Using your other hand, push the air out of the oral syringe by pushing the plunger down. Then, insert the tip of the oral syringe into the bottle adaptor at the top of the bottle. <content styleCode="bold">See <linkHtml href="#figuree">Figure E</linkHtml>
                                 </content>. The tip of the oral syringe should fit snugly into the hole of the bottle adaptor. </paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figuree">Figure E</paragraph>
                              <renderMultiMedia referencedObject="MM6"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 5: </content>Use 1 hand to hold the oral syringe in place. With the other hand, turn the bottle upside down. Pull back on the plunger until the top of the plunger lines up with the marking on the barrel of the oral syringe that matches the dose of VITRAKVI oral solution prescribed by your healthcare provider. <content styleCode="bold">See <linkHtml href="#figuref">Figure F</linkHtml>.</content> Your dose may be different than the dose shown in Figure F.</paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figuref">Figure F</paragraph>
                              <renderMultiMedia referencedObject="MM7"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 6:</content> Check for air bubbles in the oral syringe. If you see air bubbles, push up gently on the plunger to push any large air bubbles back into the bottle. Then, pull back on the plunger to the prescribed dose. <content styleCode="bold">See <linkHtml href="#figureg">Figure G</linkHtml>.</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figureg">Figure G</paragraph>
                              <renderMultiMedia referencedObject="MM8"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 7:</content> Turn the bottle upright again and place it on your work surface. Remove the oral syringe from the bottle adaptor by gently pulling up on the syringe barrel. <content styleCode="bold">See <linkHtml href="#figureh">Figure H</linkHtml>
                                 </content>. <content styleCode="bold">Do not</content> push on the plunger during this step. The bottle adaptor should stay attached to the bottle. </paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figureh">Figure H</paragraph>
                              <renderMultiMedia referencedObject="MM9"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule bold" colspan="2">
                              <paragraph>Giving a dose of VITRAKVI oral solution by mouth:</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 8:</content> Place the tip of the oral syringe into the child's mouth against the inside of the cheek. Slowly squirt VITRAKVI oral solution into the mouth by pressing down on the plunger and allow the child to swallow. <content styleCode="bold">See <linkHtml href="#figurei">Figure I</linkHtml>.</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>The child should be kept in an upright position for a few minutes right after giving a dose of VITRAKVI.</item>
                                 <item>If the child spits up a dose or you are not sure the entire dose was given, do not give another dose. Wait until the next scheduled dose.</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figurei">Figure I</paragraph>
                              <renderMultiMedia referencedObject="MM10"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 9:</content> Replace the child-resistant cap on the bottle of VITRAKVI oral solution. <content styleCode="bold">Do not</content> remove the bottle adaptor. Close the bottle by turning the bottle cap in the direction of the arrow (clockwise). <content styleCode="bold">See <linkHtml href="#figurej">Figure J</linkHtml>
                                 </content>. </paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figurej">Figure J</paragraph>
                              <renderMultiMedia referencedObject="MM11"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule bold" colspan="2">
                              <paragraph>Cleaning instructions for oral syringes</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>Follow the instructions below for cleaning the oral syringe (Step 10 through Step 16). After 7 days of use, throw away the oral syringe in your household trash. Use a new oral syringe for the next 7 days.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 10:</content> Remove plunger from the barrel of the oral syringe. <content styleCode="bold">See <linkHtml href="#figurek">Figure K</linkHtml>
                                 </content>.</paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figurek">Figure K</paragraph>
                              <renderMultiMedia referencedObject="MM12"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 11</content>: Rinse the barrel and plunger in warm running water to help make sure that all of the medicine has been removed from the oral syringe. <content styleCode="bold">See <linkHtml href="#figurel">Figure L</linkHtml>. </content>
                                 <content styleCode="bold">Do not </content>boil the oral syringe.</paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figurel">Figure L</paragraph>
                              <renderMultiMedia referencedObject="MM13"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 12:</content> Re-insert the plunger into the barrel of the oral syringe. <content styleCode="bold">See <linkHtml href="#figurem">Figure M</linkHtml>.</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figurem">Figure M</paragraph>
                              <renderMultiMedia referencedObject="MM14"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 13:</content> Draw warm water several times into the oral syringe and squirt out again until all of the medicine has been removed from the oral syringe. <content styleCode="bold">See <linkHtml href="#figuren">Figure N</linkHtml>.</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figuren">Figure N</paragraph>
                              <renderMultiMedia referencedObject="MM15"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 14:</content>  Repeat steps 10 and 11 to rinse the barrel and plunger again with warm water.  <content styleCode="bold">See <linkHtml href="#figureo">Figure O</linkHtml>
                                 </content>.</paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figureo">Figure O</paragraph>
                              <renderMultiMedia referencedObject="MM16"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Step 15:</content> Shake off excess water or wipe off the outside. <content styleCode="bold">See <linkHtml href="#figurep">Figure P</linkHtml>
                                 </content>. Place the barrel and plunger on a clean, dry paper towel to dry. </paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figurep">Figure P</paragraph>
                              <renderMultiMedia referencedObject="MM17"/>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph>
                                 <content styleCode="bold">Step 16:</content> Repeat step 12 to assemble the oral syringe and store in a clean place until the next use.  </paragraph>
                              <paragraph>Replace the oral syringe after 7 days of use, <content styleCode="bold">or</content> if:</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>there is any damage to the barrel, plunger, or tip </item>
                                 <item>the dosage marking is no longer clearly recognizable or </item>
                                 <item>it becomes difficult to move the plunger</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <paragraph styleCode="bold">How should I store VITRAKVI oral solution?</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>Store VITRAKVI oral solution in a refrigerator between 36° F to 46° F (2° C to 8° C). <content styleCode="bold">Do not</content> freeze.</item>
                                 <item>Write the date that you opened the bottle of VITRAKVI oral solution on the bottle. <content styleCode="bold">See <linkHtml href="#figureq">Figure Q</linkHtml>.</content>
                                 </item>
                                 <item>Throw away (dispose of) any unused VITRAKVI oral solution: 									<list listType="unordered" styleCode="disc">
                                       <item>Bottle of 100 mL: remaining <content styleCode="bold">90</content> days after first opening the bottle</item>
                                       <item>Bottle of 50 mL: remaining <content styleCode="bold">31</content> days after first opening the bottle</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph styleCode="bold">Keep VITRAKVI oral solution and all medicines out of the reach of children.</paragraph>
                           </td>
                           <td styleCode="Rrule" align="center">
                              <paragraph styleCode="bold" ID="figureq">Figure Q</paragraph>
                              <renderMultiMedia referencedObject="MM18"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Talk to your healthcare provider if you have questions about how to use VITRAKVI oral solution.</paragraph>
                  <paragraph>For more information, go to www.VITRAKVI.com or call 1-888-842-2937.</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Manufactured for Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981	</paragraph>
                  <paragraph>Revised: 12/2022</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM11">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM13">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM14">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM15">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM16">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM17">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM18">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vitrakvi-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="p2">
               <id root="8ba753d9-3ef9-4fc9-bf0b-a0ec31a62658"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">Package Label - 25 mg - 60 Capsules</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                     <br/>
                     <br/>
                  </paragraph>
                  <paragraph>NDC 71777-<content styleCode="bold">390</content>-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">VITRAKVI®</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(larotrectinib) capsules</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">25 mg</content>
                  </paragraph>
                  <paragraph>Usual Dosage: See prescribing information. Rx <content styleCode="bold">only.</content>
                     <br/>60 capsules. <content styleCode="bold">Keep out of reach of children.</content>
                     <br/>Store at 20°C to 25°C (68°F to 77°F).<br/>Excursions permitted from 15°C to 30°C (59° to 86°F).</paragraph>
                  <paragraph>Manufactured for Loxo Omcology, Inc. Stamford, CT 06901      86579626</paragraph>
                  <paragraph>(01)10371777390012</paragraph>
                  <paragraph>Bayer</paragraph>
                  <paragraph>LOXO</paragraph>
                  <paragraph>Each capsule contains<br/>25 mg larotrectinib<br/>(equivalent to 30.7 mg<br/>larotrectinib sulfate).</paragraph>
                  <renderMultiMedia ID="m5" referencedObject="ID_0c652fbd-66ef-4850-adfe-b3d93368ebb1"/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="ID_0c652fbd-66ef-4850-adfe-b3d93368ebb1">
                     <text>image of 25 mg label principal panel - 60 capsules</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="vitrakvi-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="p4">
               <id root="c32600f7-ee3a-4365-a13e-741657ac6f89"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">Package Label - 100 mg - 60 Capsules</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                     <br/>
                     <br/>
                  </paragraph>
                  <paragraph>NDC 71777-<content styleCode="bold">391</content>-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">VITRAKVI®</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(larotrectinib) capsules</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">100 mg</content>
                  </paragraph>
                  <paragraph>Usual Dosage: See prescribing information.</paragraph>
                  <paragraph>Rx <content styleCode="bold">only.</content> 60 capsules. <content styleCode="bold">Keep out of reach of children.</content>
                     <br/>Store at 20°C to 25°C (68°F to 77°F).<br/>Excursions permitted from 15°C to 30°C (59° to 86°F).</paragraph>
                  <paragraph>Manufactured for Loxo Omcology, Inc. Stamford, CT 06901      86579634</paragraph>
                  <paragraph>(01)10371777391019</paragraph>
                  <paragraph>Bayer</paragraph>
                  <paragraph>LOXO</paragraph>
                  <paragraph>Each capsule<br/>contains 100 mg<br/>larotrectinib<br/>(equivalent to<br/>123 mg<br/>larotrectinib<br/>sulfate).</paragraph>
                  <renderMultiMedia ID="m6" referencedObject="ID_32d523bc-0bc2-4455-b5e5-8b3b80926d22"/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="ID_32d523bc-0bc2-4455-b5e5-8b3b80926d22">
                     <text>image of 100 mg label principal panel - 60 capsules</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="vitrakvi-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="p6">
               <id root="962e6635-7b76-47f3-b8cb-efcc44a4d4d9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">Package Label - 20 mg/mL - 100 mL Oral Solution</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                     <br/>
                     <br/>
                  </paragraph>
                  <paragraph>NDC 71777-<content styleCode="bold">392</content>-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">VITRAKVI®</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(larotrectinib) oral solution</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">20 mg/mL</content>
                  </paragraph>
                  <paragraph>Usual Dosage: See prescribing information. <content styleCode="bold">Keep refrigerated. Store at 2°C to 8°C (36°F to 46°F). Rx only.</content>
                     <br/>
                     <content styleCode="bold">Date of first opening ____/____/____. Discard unused portion 90 days after first opening.</content>
                     <br/>100 mL oral solution. <content styleCode="bold">Keep out of reach of children.</content>
                  </paragraph>
                  <paragraph>Manufactured for Loxo Omcology, Inc. Stamford, CT 06901      86659069</paragraph>
                  <paragraph>(01)10371777392016</paragraph>
                  <paragraph>Bayer</paragraph>
                  <paragraph>LOXO</paragraph>
                  <paragraph>Each bottle contains<br/>100 ml of 20 mg/mL<br/>larotrectinib (equivalent<br/>to 24.6 mg/mL<br/>larotrectinib sulfate).</paragraph>
                  <renderMultiMedia ID="m7" referencedObject="ID_5b632a84-f318-4ec1-9a17-50f2ce2143b8"/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="ID_5b632a84-f318-4ec1-9a17-50f2ce2143b8">
                     <text>image of 20 mg/mL label principal panel - 100 mL oral solution</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="vitrakvi-21.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8fb01df2-8be1-4875-b3f3-f5416d8247be">
               <id root="1cdd8b0b-5cc6-4321-9a87-fe7382ba79a4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel </title>
               <text>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">Package Label - 20 mg/mL - 50 mL Oral Solution</content>
                  </paragraph>
                  <paragraph>NDC 50419-<content styleCode="bold">393</content>-02</paragraph>
                  <paragraph>
                     <content styleCode="bold">VITRAKVI®</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(larotrectinib) oral solution</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">20 mg/mL</content>
                  </paragraph>
                  <paragraph>RECOMMENDED DOSAGE: See prescribing information. <content styleCode="bold">Keep refrigerated. Store at 2°C to 8°C (36°F to 46°F). Rx only.</content>
                     <br/>
                     <content styleCode="bold">Date of first opening ____/____/____. Discard unused portion 31 days after first opening.</content>
                     <br/>50 mL oral solution. <content styleCode="bold">For Oral Administration Only.</content>
                     <content styleCode="bold">Keep out of reach of children.</content>
                  </paragraph>
                  <paragraph>Manufactured for Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981 88735951</paragraph>
                  <paragraph>(01)10350419393024</paragraph>
                  <paragraph>Bayer</paragraph>
                  <paragraph>Each bottle contains<br/>50 mL of 20 mg/mL<br/>larotrectinib (equivalent<br/>to 24.6 mg/mL<br/>larotrectinib sulfate).</paragraph>
                  <renderMultiMedia ID="id-1084598832" referencedObject="ID_530d8f24-cda1-49a4-b56d-2b560b4085e0"/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="ID_530d8f24-cda1-49a4-b56d-2b560b4085e0">
                     <text>Package Label - 20 mg/mL - 50 mL Oral Solution NDC 50419-393-02 VITRAKVI® (larotrectinib) oral solution 20 mg/mL RECOMMENDED DOSAGE: See prescribing information. Keep refrigerated. Store at 2°C to 8°C (36°F to 46°F). Rx only. Date of first opening ____/____/____. Discard unused portion 31 days after first opening. 50 mL oral solution. For Oral Administration Only. Keep out of reach of children. Manufactured for Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981 88735951 (01)10350419393024 Bayer Each bottle contains 50 mL of 20 mg/mL larotrectinib (equivalent to 24.6 mg/mL larotrectinib sulfate).</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="vitrakvi-22.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>